data_5mxl_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5mxl _Structure_validation_residue.Date_analyzed 2017-03-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.5 mt . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.4 t -65.08 -39.31 85.17 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 O-C-N 122.189 -0.32 . . . . 0.0 110.846 -178.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -66.66 -28.12 68.21 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 122.073 -0.392 . . . . 0.0 111.246 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -74.5 -30.24 61.73 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 117.759 0.254 . . . . 0.0 110.845 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -38.79 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.93 -28.95 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.8 -29.47 74.86 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.04 -27.29 63.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 117.183 0.491 . . . . 0.0 110.689 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.2 mt -81.13 3.43 23.54 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.113 0.565 . . . . 0.0 111.016 177.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.769 0 N-CA-C 111.884 -0.487 . . . . 0.0 111.884 -177.594 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 70.5 mt . . . . . 0 N--CA 1.452 -0.359 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -69.62 -34.25 60.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 C-N-CA 122.088 0.155 . . . . 0.0 110.868 -179.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -62.92 -27.98 69.74 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.72 0.408 . . . . 0.0 111.777 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -78.01 -29.61 49.64 Favored 'General case' 0 C--N 1.338 0.089 0 CA-C-N 117.853 0.297 . . . . 0.0 111.241 176.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.1 t -75.91 -40.6 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.0 -29.4 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.46 -29.01 73.93 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.439 -0.664 . . . . 0.0 111.439 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.08 -26.72 64.13 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.589 0.694 . . . . 0.0 110.745 177.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.6 mt -81.85 3.66 25.23 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.249 0.62 . . . . 0.0 111.173 177.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.887 0 N-CA-C 111.839 -0.504 . . . . 0.0 111.839 -177.682 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 N--CA 1.456 -0.171 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -68.28 -36.03 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.065 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -64.38 -25.59 68.09 Favored 'General case' 0 C--N 1.339 0.139 0 CA-C-N 118.274 0.488 . . . . 0.0 111.656 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -79.87 -29.95 40.1 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.077 0.399 . . . . 0.0 111.127 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.3 t -74.51 -40.77 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.87 -29.41 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.75 72.99 Favored Glycine 0 C--N 1.338 0.654 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 178.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.62 -26.3 63.42 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 117.591 0.695 . . . . 0.0 110.751 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 53.0 mt -82.91 4.82 24.11 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.336 0.654 . . . . 0.0 111.176 177.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.037 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.58 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.7 mt . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.42 -40.64 87.11 Favored 'Isoleucine or valine' 0 C--N 1.34 0.174 0 N-CA-C 110.008 -0.368 . . . . 0.0 110.008 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -67.73 -26.93 66.39 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 122.279 -0.263 . . . . 0.0 111.372 179.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -73.1 -32.39 64.94 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 117.832 0.287 . . . . 0.0 110.753 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.2 t -76.61 -38.04 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 63.1 t -70.48 -29.22 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.94 -28.95 73.51 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.33 -27.01 64.03 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.524 0.662 . . . . 0.0 110.469 177.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.2 mt -82.24 3.73 26.33 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 123.244 0.618 . . . . 0.0 111.108 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.921 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -177.368 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.457 -0.104 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 94.6 t -67.73 -40.84 84.6 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -67.09 -25.83 66.42 Favored 'General case' 0 CA--C 1.529 0.155 0 O-C-N 122.072 -0.392 . . . . 0.0 111.274 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -73.88 -31.57 63.2 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 117.788 0.267 . . . . 0.0 110.632 177.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.9 t -76.02 -38.42 35.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 76.5 t -69.51 -29.52 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.32 -29.12 74.15 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.86 -26.63 63.35 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 117.586 0.693 . . . . 0.0 110.55 177.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.1 mt -81.7 4.79 20.55 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.05 0.54 . . . . 0.0 110.933 177.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.879 0 N-CA-C 111.749 -0.54 . . . . 0.0 111.749 -177.969 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.3 mt . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -67.58 -40.17 83.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -66.39 -27.18 67.66 Favored 'General case' 0 C--N 1.338 0.109 0 O-C-N 122.129 -0.357 . . . . 0.0 111.619 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -73.17 -31.06 64.0 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 117.65 0.204 . . . . 0.0 110.701 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -77.03 -38.55 28.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 69.7 t -69.19 -29.1 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.69 -28.96 73.37 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.571 -0.612 . . . . 0.0 111.571 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.12 63.05 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 117.515 0.657 . . . . 0.0 110.554 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.5 mt -83.44 5.16 24.7 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.346 0.658 . . . . 0.0 111.197 177.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.817 0 N-CA-C 111.84 -0.504 . . . . 0.0 111.84 -177.834 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 83.4 mt . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 97.3 t -66.51 -41.28 88.26 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -67.07 -27.01 67.01 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 122.253 -0.279 . . . . 0.0 111.614 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.3 -32.63 64.73 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 122.271 0.229 . . . . 0.0 110.697 177.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.6 t -75.79 -38.21 36.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 64.4 t -70.17 -28.94 37.7 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.7 -27.89 72.58 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.496 -0.641 . . . . 0.0 111.496 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.54 -26.54 62.69 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 117.479 0.64 . . . . 0.0 110.587 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.1 mt -81.48 3.54 24.38 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.318 0.647 . . . . 0.0 111.082 178.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.784 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -177.178 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.452 -0.337 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 90.0 t -64.7 -40.68 89.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.07 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -67.54 -27.75 67.22 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 117.805 0.275 . . . . 0.0 111.173 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -74.28 -31.61 62.59 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 117.931 0.332 . . . . 0.0 111.03 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 47.6 t -74.72 -37.95 43.84 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.6 t -71.85 -29.21 32.73 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.39 -29.49 74.72 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 179.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.19 -26.81 65.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 117.295 0.547 . . . . 0.0 110.68 177.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.9 mt -82.73 3.77 27.86 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.93 0.492 . . . . 0.0 111.064 178.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.822 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.54 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.0 mt . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.96 -42.27 95.21 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.094 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -69.02 -27.15 65.42 Favored 'General case' 0 N--CA 1.457 -0.091 0 O-C-N 122.203 -0.31 . . . . 0.0 110.945 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -71.92 -31.81 66.73 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 122.569 0.348 . . . . 0.0 110.599 177.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 51.3 t -75.49 -36.92 36.49 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.15 -29.37 39.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.71 -28.19 72.2 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 178.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.61 -27.02 63.76 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 117.239 0.519 . . . . 0.0 110.675 177.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -82.72 4.57 24.54 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.261 0.625 . . . . 0.0 111.131 178.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.885 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.34 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 93.0 mt . . . . . 0 N--CA 1.457 -0.119 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.4 t -63.18 -35.67 72.87 Favored 'Isoleucine or valine' 0 C--O 1.23 0.073 0 N-CA-C 111.572 0.212 . . . . 0.0 111.572 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -64.67 -27.4 68.9 Favored 'General case' 0 N--CA 1.457 -0.098 0 O-C-N 121.861 -0.525 . . . . 0.0 111.139 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -76.22 -29.82 57.71 Favored 'General case' 0 N--CA 1.461 0.092 0 CA-C-N 117.716 0.234 . . . . 0.0 110.715 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 71.9 t -75.02 -40.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -68.91 -29.32 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.08 -29.51 74.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.79 -0.524 . . . . 0.0 111.79 178.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.06 -27.02 64.29 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.384 0.592 . . . . 0.0 110.857 177.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.0 mt -82.25 3.76 26.21 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.193 0.597 . . . . 0.0 111.099 177.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.887 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.892 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 79.3 mt . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 82.6 t -65.75 -41.42 90.29 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -68.82 -27.5 65.9 Favored 'General case' 0 C--N 1.334 -0.103 0 O-C-N 122.356 -0.215 . . . . 0.0 111.363 178.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -71.94 -31.88 66.77 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 122.359 0.263 . . . . 0.0 110.843 177.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.19 -38.12 33.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.9 t -69.28 -29.27 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 177.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.59 -28.16 72.07 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.07 -26.01 62.0 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 117.515 0.657 . . . . 0.0 110.41 178.137 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -82.48 4.74 23.11 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.219 0.608 . . . . 0.0 111.251 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.818 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -177.969 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 92.4 mt . . . . . 0 CA--C 1.529 0.167 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -62.68 -34.84 67.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 122.157 -0.339 . . . . 0.0 110.725 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.01 -28.19 69.93 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 117.937 0.335 . . . . 0.0 111.413 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.82 -29.67 44.91 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 117.702 0.228 . . . . 0.0 110.731 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.8 t -74.46 -40.05 48.56 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 77.3 t -71.66 -29.0 32.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.06 -29.17 74.13 Favored Glycine 0 C--N 1.339 0.699 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.2 -26.17 64.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 117.56 0.68 . . . . 0.0 110.763 177.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.1 mt -83.21 5.23 23.58 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 123.196 0.599 . . . . 0.0 111.238 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.043 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -177.913 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.4 mt . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.7 -40.35 88.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -66.96 -28.49 68.32 Favored 'General case' 0 N--CA 1.457 -0.093 0 O-C-N 122.075 -0.391 . . . . 0.0 111.227 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.86 -33.7 62.14 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.762 0.255 . . . . 0.0 110.75 178.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 49.8 t -73.41 -39.52 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.131 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -71.2 -29.44 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.01 -29.46 74.95 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.67 -26.1 63.29 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 117.346 0.573 . . . . 0.0 110.751 178.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.79 3.31 26.3 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.933 0.493 . . . . 0.0 111.189 177.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.924 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -177.695 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.8 mt . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.4 t -63.57 -41.03 91.22 Favored 'Isoleucine or valine' 0 C--O 1.23 0.039 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 178.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -70.06 -28.79 65.74 Favored 'General case' 0 C--N 1.34 0.152 0 O-C-N 122.303 -0.248 . . . . 0.0 110.937 177.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -71.76 -32.45 67.7 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 122.511 0.324 . . . . 0.0 110.927 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.6 t -73.69 -36.35 46.52 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.5 t -71.04 -29.47 37.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 177.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.28 -28.67 73.33 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.82 -25.66 62.95 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.33 0.565 . . . . 0.0 110.867 178.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -81.75 3.99 23.67 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 123.069 0.547 . . . . 0.0 111.128 177.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.78 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -177.241 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.9 mt . . . . . 0 N--CA 1.453 -0.277 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 86.0 t -63.83 -40.1 87.81 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -67.46 -28.56 67.98 Favored 'General case' 0 N--CA 1.456 -0.173 0 O-C-N 122.341 -0.224 . . . . 0.0 111.33 177.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.57 -32.22 62.33 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.155 0.182 . . . . 0.0 111.029 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 46.8 t -73.38 -38.16 52.81 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.51 -29.19 34.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.53 -28.99 73.3 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.07 -26.75 64.15 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 117.592 0.696 . . . . 0.0 110.421 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.7 mt -82.88 3.91 27.77 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.292 0.637 . . . . 0.0 111.128 177.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.858 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -177.312 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 81.3 mt . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 98.1 t -63.43 -40.49 89.25 Favored 'Isoleucine or valine' 0 C--N 1.339 0.121 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -67.42 -28.52 67.97 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.289 -0.257 . . . . 0.0 111.165 177.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.19 -32.43 63.07 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.709 0.231 . . . . 0.0 110.954 178.102 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.6 t -75.33 -38.08 39.87 Favored 'Isoleucine or valine' 0 C--N 1.338 0.081 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.9 t -70.16 -29.08 38.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 177.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.98 -28.76 73.25 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.57 -26.61 63.61 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 117.705 0.753 . . . . 0.0 110.642 177.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.0 mt -82.83 4.34 25.83 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.193 0.597 . . . . 0.0 111.295 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.052 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 -178.044 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.1 mt . . . . . 0 N--CA 1.452 -0.365 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -62.56 -34.16 63.5 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.106 0 O-C-N 122.33 -0.231 . . . . 0.0 110.598 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.86 -26.42 68.6 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 122.253 -0.28 . . . . 0.0 111.395 177.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -75.42 -29.92 59.88 Favored 'General case' 0 C--N 1.337 0.051 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 177.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 95.5 t -76.87 -41.77 32.55 Favored 'Isoleucine or valine' 0 C--N 1.339 0.116 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 80.9 t -69.81 -29.46 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.1 -29.45 74.45 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.45 -27.25 64.1 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 117.492 0.646 . . . . 0.0 110.757 178.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.55 3.87 23.42 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.406 0.682 . . . . 0.0 111.101 177.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.013 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 -177.889 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 97.1 mt . . . . . 0 N--CA 1.453 -0.275 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -66.99 -41.85 87.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 O-C-N 122.418 -0.176 . . . . 0.0 110.886 -178.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.9 mmtp -67.51 -26.99 66.61 Favored 'General case' 0 CA--C 1.527 0.092 0 O-C-N 122.24 -0.287 . . . . 0.0 111.028 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.46 -31.75 63.95 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 117.657 0.208 . . . . 0.0 110.467 178.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 50.8 t -76.19 -37.84 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.098 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.3 t -69.61 -29.0 39.73 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.58 -29.36 74.41 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.4 -26.41 63.68 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.482 0.641 . . . . 0.0 110.226 178.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.4 mt -82.7 4.0 26.81 Favored 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.218 0.607 . . . . 0.0 111.074 178.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.948 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 -177.442 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 N--CA 1.454 -0.261 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.5 t -66.04 -35.81 75.95 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.085 0 C-N-CA 122.317 0.247 . . . . 0.0 110.987 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.3 mptp? -65.13 -29.01 69.83 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.102 -0.374 . . . . 0.0 110.75 177.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -76.5 -29.73 56.94 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.934 0.334 . . . . 0.0 110.826 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.8 t -73.54 -39.0 53.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 177.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.4 t -70.1 -29.26 39.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 176.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.47 -28.82 73.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.05 -26.67 64.14 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 117.493 0.646 . . . . 0.0 110.601 177.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.3 mt -82.44 3.8 26.76 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.295 0.638 . . . . 0.0 111.072 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.862 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -177.59 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 91.8 mt . . . . . 0 N--CA 1.455 -0.224 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.0 t -63.21 -37.88 80.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 O-C-N 122.349 -0.219 . . . . 0.0 110.84 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm -65.76 -28.8 69.29 Favored 'General case' 0 C--N 1.34 0.153 0 O-C-N 122.194 -0.316 . . . . 0.0 111.236 178.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . 0.47 ' HB2' ' HZ3' ' A' ' 8' ' ' LYS . 4.4 ttmp? -75.25 -31.64 60.86 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 117.751 0.25 . . . . 0.0 110.694 178.054 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t -73.96 -39.09 50.91 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.4 -29.52 39.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.57 -29.08 73.59 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.85 -26.97 64.46 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.369 0.584 . . . . 0.0 110.651 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.3 mt -81.64 3.26 25.97 Favored 'General case' 0 N--CA 1.457 -0.087 0 C-N-CA 123.264 0.626 . . . . 0.0 110.966 177.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.942 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 -177.68 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.037 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.7 tp -154.96 -29.44 0.11 Allowed 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 122.756 0.422 . . . . 0.0 111.943 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -55.89 -29.09 59.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -63.52 -28.26 69.83 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 120.318 -0.553 . . . . 0.0 111.868 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.5 mt -80.28 -38.77 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 122.907 0.483 . . . . 0.0 109.83 176.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.4 t -65.08 -39.31 85.17 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 O-C-N 122.189 -0.32 . . . . 0.0 110.846 -178.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -66.66 -28.12 68.21 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 122.073 -0.392 . . . . 0.0 111.246 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -74.5 -30.24 61.73 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 117.759 0.254 . . . . 0.0 110.845 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -38.79 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.93 -28.95 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.8 -29.47 74.86 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.04 -27.29 63.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 117.183 0.491 . . . . 0.0 110.689 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.2 mt -81.13 3.43 23.54 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.113 0.565 . . . . 0.0 111.016 177.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.16 7.01 88.32 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.884 -0.487 . . . . 0.0 111.884 -177.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.131 0 CA-C-N 117.961 0.881 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.056 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 63.8 tp -153.64 -28.13 0.13 Allowed 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 122.66 0.384 . . . . 0.0 111.897 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -54.05 -35.54 62.1 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 116.658 2.096 . . . . 0.0 116.658 -178.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -66.48 -22.68 66.19 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 70.5 mt -80.73 -41.4 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 174.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -69.62 -34.25 60.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 C-N-CA 122.088 0.155 . . . . 0.0 110.868 -179.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -62.92 -27.98 69.74 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.72 0.408 . . . . 0.0 111.777 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -78.01 -29.61 49.64 Favored 'General case' 0 C--N 1.338 0.089 0 CA-C-N 117.853 0.297 . . . . 0.0 111.241 176.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.1 t -75.91 -40.6 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.377 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.0 -29.4 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.46 -29.01 73.93 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.439 -0.664 . . . . 0.0 111.439 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.08 -26.72 64.13 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.589 0.694 . . . . 0.0 110.745 177.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.6 mt -81.85 3.66 25.23 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.249 0.62 . . . . 0.0 111.173 177.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.83 8.45 86.73 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.839 -0.504 . . . . 0.0 111.839 -177.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.17 0 CA-C-N 117.856 0.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.043 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.4 tp -153.18 -29.37 0.14 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.742 0.417 . . . . 0.0 111.762 -179.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -55.38 -31.19 61.6 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -65.0 -25.14 67.73 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt -82.52 -42.57 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 C-N-CA 122.682 0.393 . . . . 0.0 110.201 174.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -68.28 -36.03 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.065 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -64.38 -25.59 68.09 Favored 'General case' 0 C--N 1.339 0.139 0 CA-C-N 118.274 0.488 . . . . 0.0 111.656 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -79.87 -29.95 40.1 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.077 0.399 . . . . 0.0 111.127 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.3 t -74.51 -40.77 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.87 -29.41 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.75 72.99 Favored Glycine 0 C--N 1.338 0.654 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 178.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.62 -26.3 63.42 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 117.591 0.695 . . . . 0.0 110.751 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 53.0 mt -82.91 4.82 24.11 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.336 0.654 . . . . 0.0 111.176 177.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 6.59 88.58 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.153 0 CA-C-N 117.886 0.843 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.926 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.3 tp -152.25 -28.03 0.17 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.549 0.34 . . . . 0.0 111.688 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.7 m-85 -56.5 -29.55 61.95 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 116.644 2.09 . . . . 0.0 116.644 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -66.5 -28.66 68.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.651 -0.42 . . . . 0.0 112.004 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.7 mt -80.17 -39.91 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 C-N-CA 122.777 0.431 . . . . 0.0 110.014 177.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.42 -40.64 87.11 Favored 'Isoleucine or valine' 0 C--N 1.34 0.174 0 N-CA-C 110.008 -0.368 . . . . 0.0 110.008 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -67.73 -26.93 66.39 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 122.279 -0.263 . . . . 0.0 111.372 179.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -73.1 -32.39 64.94 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 117.832 0.287 . . . . 0.0 110.753 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.2 t -76.61 -38.04 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 63.1 t -70.48 -29.22 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.94 -28.95 73.51 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.33 -27.01 64.03 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.524 0.662 . . . . 0.0 110.469 177.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.2 mt -82.24 3.73 26.33 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 123.244 0.618 . . . . 0.0 111.108 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.42 7.65 88.03 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.061 0 CA-C-N 117.764 0.782 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.114 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 61.5 tp -82.4 -25.94 33.26 Favored 'General case' 0 CA--C 1.524 -0.034 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -56.37 -29.54 61.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -67.88 -29.05 68.06 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.56 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.3 mt -80.07 -39.18 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 94.6 t -67.73 -40.84 84.6 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -67.09 -25.83 66.42 Favored 'General case' 0 CA--C 1.529 0.155 0 O-C-N 122.072 -0.392 . . . . 0.0 111.274 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -73.88 -31.57 63.2 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 117.788 0.267 . . . . 0.0 110.632 177.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.9 t -76.02 -38.42 35.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 76.5 t -69.51 -29.52 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.32 -29.12 74.15 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.86 -26.63 63.35 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 117.586 0.693 . . . . 0.0 110.55 177.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.1 mt -81.7 4.79 20.55 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.05 0.54 . . . . 0.0 110.933 177.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 7.88 87.88 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.749 -0.54 . . . . 0.0 111.749 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.137 0 CA-C-N 117.836 0.818 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.042 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.8 tp -152.95 -28.32 0.15 Allowed 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.662 0.385 . . . . 0.0 111.421 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -56.28 -29.31 61.0 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 116.762 2.134 . . . . 0.0 116.762 -179.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -66.75 -28.42 68.4 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 178.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.3 mt -80.63 -39.51 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 122.803 0.441 . . . . 0.0 109.907 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -67.58 -40.17 83.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -66.39 -27.18 67.66 Favored 'General case' 0 C--N 1.338 0.109 0 O-C-N 122.129 -0.357 . . . . 0.0 111.619 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -73.17 -31.06 64.0 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 117.65 0.204 . . . . 0.0 110.701 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -77.03 -38.55 28.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 69.7 t -69.19 -29.1 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.69 -28.96 73.37 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.571 -0.612 . . . . 0.0 111.571 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.12 63.05 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 117.515 0.657 . . . . 0.0 110.554 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.5 mt -83.44 5.16 24.7 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.346 0.658 . . . . 0.0 111.197 177.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.94 6.39 88.42 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.84 -0.504 . . . . 0.0 111.84 -177.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.098 0 CA-C-N 117.785 0.793 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.096 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.0 tp -154.12 -27.5 0.13 Allowed 'General case' 0 C--O 1.232 0.168 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -56.72 -29.53 62.58 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 116.894 2.183 . . . . 0.0 116.894 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -66.81 -28.87 68.72 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.048 178.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 83.4 mt -80.04 -39.65 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.086 0.554 . . . . 0.0 109.804 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 97.3 t -66.51 -41.28 88.26 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -67.07 -27.01 67.01 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 122.253 -0.279 . . . . 0.0 111.614 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.3 -32.63 64.73 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 122.271 0.229 . . . . 0.0 110.697 177.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.6 t -75.79 -38.21 36.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 64.4 t -70.17 -28.94 37.7 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.7 -27.89 72.58 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.496 -0.641 . . . . 0.0 111.496 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.54 -26.54 62.69 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 117.479 0.64 . . . . 0.0 110.587 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.1 mt -81.48 3.54 24.38 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.318 0.647 . . . . 0.0 111.082 178.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.17 7.02 88.31 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -177.178 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.018 0 O-C-N 121.772 -0.84 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.056 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 60.8 tp -83.87 -25.6 30.11 Favored 'General case' 0 C--N 1.334 -0.103 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -56.87 -29.37 62.86 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 116.494 2.035 . . . . 0.0 116.494 -178.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -66.78 -29.21 69.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.732 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -79.82 -36.55 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 C-N-CA 122.826 0.45 . . . . 0.0 109.899 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 90.0 t -64.7 -40.68 89.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.07 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -67.54 -27.75 67.22 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 117.805 0.275 . . . . 0.0 111.173 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -74.28 -31.61 62.59 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 117.931 0.332 . . . . 0.0 111.03 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 47.6 t -74.72 -37.95 43.84 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.6 t -71.85 -29.21 32.73 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.39 -29.49 74.72 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 179.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.19 -26.81 65.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 117.295 0.547 . . . . 0.0 110.68 177.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.9 mt -82.73 3.77 27.86 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.93 0.492 . . . . 0.0 111.064 178.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 6.54 88.69 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.066 0 CA-C-N 117.632 0.716 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.012 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 68.0 tp -154.94 -29.24 0.11 Allowed 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 122.687 0.395 . . . . 0.0 111.722 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -55.63 -29.12 58.65 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 117.256 2.317 . . . . 0.0 117.256 -178.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -63.76 -29.07 70.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 120.051 -0.66 . . . . 0.0 111.59 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.0 mt -80.64 -37.23 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 123.141 0.576 . . . . 0.0 109.78 176.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.96 -42.27 95.21 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.094 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -69.02 -27.15 65.42 Favored 'General case' 0 N--CA 1.457 -0.091 0 O-C-N 122.203 -0.31 . . . . 0.0 110.945 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -71.92 -31.81 66.73 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 122.569 0.348 . . . . 0.0 110.599 177.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 51.3 t -75.49 -36.92 36.49 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.15 -29.37 39.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.71 -28.19 72.2 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 178.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.61 -27.02 63.76 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 117.239 0.519 . . . . 0.0 110.675 177.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -82.72 4.57 24.54 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.261 0.625 . . . . 0.0 111.131 178.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.92 6.05 89.27 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.115 0 CA-C-N 117.798 0.799 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.083 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.6 tp -154.86 -30.32 0.11 Allowed 'General case' 0 CA--C 1.528 0.111 0 C-N-CA 122.555 0.342 . . . . 0.0 111.634 179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . 0.259 30.7 m-85 -55.26 -29.08 57.39 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 117.309 2.337 . . . . 0.0 117.309 -178.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -62.65 -28.61 70.04 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 120.517 -0.473 . . . . 0.0 111.667 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 93.0 mt -80.89 -38.31 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 C-N-CA 123.141 0.577 . . . . 0.0 110.005 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.4 t -63.18 -35.67 72.87 Favored 'Isoleucine or valine' 0 C--O 1.23 0.073 0 N-CA-C 111.572 0.212 . . . . 0.0 111.572 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -64.67 -27.4 68.9 Favored 'General case' 0 N--CA 1.457 -0.098 0 O-C-N 121.861 -0.525 . . . . 0.0 111.139 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -76.22 -29.82 57.71 Favored 'General case' 0 N--CA 1.461 0.092 0 CA-C-N 117.716 0.234 . . . . 0.0 110.715 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 71.9 t -75.02 -40.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -68.91 -29.32 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.08 -29.51 74.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.79 -0.524 . . . . 0.0 111.79 178.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.06 -27.02 64.29 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.384 0.592 . . . . 0.0 110.857 177.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.0 mt -82.25 3.76 26.21 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.193 0.597 . . . . 0.0 111.099 177.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.97 6.21 89.11 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.134 0 CA-C-N 117.671 0.736 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.041 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.6 tp -152.68 -28.73 0.15 Allowed 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 122.814 0.446 . . . . 0.0 111.868 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -55.94 -29.63 60.42 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 117.03 2.233 . . . . 0.0 117.03 -179.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -67.05 -29.35 69.11 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.126 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 79.3 mt -80.23 -38.45 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 C-N-CA 122.786 0.434 . . . . 0.0 109.906 177.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 82.6 t -65.75 -41.42 90.29 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -68.82 -27.5 65.9 Favored 'General case' 0 C--N 1.334 -0.103 0 O-C-N 122.356 -0.215 . . . . 0.0 111.363 178.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -71.94 -31.88 66.77 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 122.359 0.263 . . . . 0.0 110.843 177.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.19 -38.12 33.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.9 t -69.28 -29.27 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 177.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.59 -28.16 72.07 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.07 -26.01 62.0 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 117.515 0.657 . . . . 0.0 110.41 178.137 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -82.48 4.74 23.11 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.219 0.608 . . . . 0.0 111.251 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.26 7.36 87.79 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.084 0 CA-C-N 118.017 0.909 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.021 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.3 tp -154.52 -30.47 0.11 Allowed 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 122.563 0.345 . . . . 0.0 111.854 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -55.87 -29.37 59.82 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 116.67 2.1 . . . . 0.0 116.67 -177.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -63.32 -28.4 69.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 120.479 -0.489 . . . . 0.0 111.823 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 92.4 mt -80.06 -36.83 17.12 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -62.68 -34.84 67.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 122.157 -0.339 . . . . 0.0 110.725 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.01 -28.19 69.93 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 117.937 0.335 . . . . 0.0 111.413 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.82 -29.67 44.91 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 117.702 0.228 . . . . 0.0 110.731 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.8 t -74.46 -40.05 48.56 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 77.3 t -71.66 -29.0 32.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.06 -29.17 74.13 Favored Glycine 0 C--N 1.339 0.699 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.2 -26.17 64.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 117.56 0.68 . . . . 0.0 110.763 177.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.1 mt -83.21 5.23 23.58 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 123.196 0.599 . . . . 0.0 111.238 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 6.12 89.05 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -177.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.133 0 CA-C-N 117.757 0.778 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.012 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.8 tp -154.34 -29.4 0.12 Allowed 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 122.466 0.307 . . . . 0.0 111.73 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -56.08 -29.12 60.11 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 116.88 2.178 . . . . 0.0 116.88 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -65.58 -28.05 68.86 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.959 178.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.4 mt -80.02 -37.31 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 175.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.7 -40.35 88.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -66.96 -28.49 68.32 Favored 'General case' 0 N--CA 1.457 -0.093 0 O-C-N 122.075 -0.391 . . . . 0.0 111.227 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.86 -33.7 62.14 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.762 0.255 . . . . 0.0 110.75 178.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 49.8 t -73.41 -39.52 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.131 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -71.2 -29.44 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.01 -29.46 74.95 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.67 -26.1 63.29 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 117.346 0.573 . . . . 0.0 110.751 178.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.79 3.31 26.3 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.933 0.493 . . . . 0.0 111.189 177.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.94 8.79 86.2 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -177.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.029 0 CA-C-N 117.688 0.744 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.027 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.6 tp -153.71 -28.05 0.13 Allowed 'General case' 0 CA--C 1.527 0.077 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -56.54 -29.44 61.95 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 116.736 2.125 . . . . 0.0 116.736 -178.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -65.57 -28.71 69.34 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 120.443 -0.503 . . . . 0.0 112.051 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.8 mt -80.47 -35.16 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 C-N-CA 123.003 0.521 . . . . 0.0 110.045 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.4 t -63.57 -41.03 91.22 Favored 'Isoleucine or valine' 0 C--O 1.23 0.039 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 178.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -70.06 -28.79 65.74 Favored 'General case' 0 C--N 1.34 0.152 0 O-C-N 122.303 -0.248 . . . . 0.0 110.937 177.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -71.76 -32.45 67.7 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 122.511 0.324 . . . . 0.0 110.927 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.6 t -73.69 -36.35 46.52 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.5 t -71.04 -29.47 37.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 177.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.28 -28.67 73.33 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.82 -25.66 62.95 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.33 0.565 . . . . 0.0 110.867 178.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -81.75 3.99 23.67 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 123.069 0.547 . . . . 0.0 111.128 177.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.97 7.13 88.29 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -177.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.104 0 CA-C-N 118.054 0.927 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.921 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 68.4 tp -154.18 -28.64 0.12 Allowed 'General case' 0 CA--C 1.528 0.112 0 C-N-CA 122.466 0.306 . . . . 0.0 111.666 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -56.12 -29.14 60.24 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 117.218 2.303 . . . . 0.0 117.218 -178.227 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -65.38 -28.36 69.22 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.786 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.9 mt -79.91 -36.74 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 176.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 86.0 t -63.83 -40.1 87.81 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -67.46 -28.56 67.98 Favored 'General case' 0 N--CA 1.456 -0.173 0 O-C-N 122.341 -0.224 . . . . 0.0 111.33 177.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.57 -32.22 62.33 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.155 0.182 . . . . 0.0 111.029 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 46.8 t -73.38 -38.16 52.81 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.51 -29.19 34.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.53 -28.99 73.3 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.07 -26.75 64.15 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 117.592 0.696 . . . . 0.0 110.421 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.7 mt -82.88 3.91 27.77 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.292 0.637 . . . . 0.0 111.128 177.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.5 6.74 88.96 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -177.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.042 0 CA-C-N 117.595 0.698 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.073 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.5 tp -154.11 -28.48 0.12 Allowed 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.7 m-85 -56.16 -29.29 60.59 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 117.064 2.246 . . . . 0.0 117.064 -178.103 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -65.98 -28.1 68.63 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.51 -0.476 . . . . 0.0 112.114 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 81.3 mt -80.04 -37.35 17.63 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 176.364 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 98.1 t -63.43 -40.49 89.25 Favored 'Isoleucine or valine' 0 C--N 1.339 0.121 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -67.42 -28.52 67.97 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.289 -0.257 . . . . 0.0 111.165 177.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.19 -32.43 63.07 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.709 0.231 . . . . 0.0 110.954 178.102 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.6 t -75.33 -38.08 39.87 Favored 'Isoleucine or valine' 0 C--N 1.338 0.081 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.9 t -70.16 -29.08 38.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 177.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.98 -28.76 73.25 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.57 -26.61 63.61 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 117.705 0.753 . . . . 0.0 110.642 177.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.0 mt -82.83 4.34 25.83 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.193 0.597 . . . . 0.0 111.295 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.27 6.73 88.49 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 -178.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.12 0 CA-C-N 117.807 0.804 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.86 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.9 tp -154.93 -30.32 0.1 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 122.698 -0.295 . . . . 0.0 111.73 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -55.72 -29.64 59.81 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 116.919 2.192 . . . . 0.0 116.919 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -63.21 -27.63 69.49 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.153 177.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.1 mt -80.6 -36.6 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 C-N-CA 123.177 0.591 . . . . 0.0 109.944 175.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -62.56 -34.16 63.5 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.106 0 O-C-N 122.33 -0.231 . . . . 0.0 110.598 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.86 -26.42 68.6 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 122.253 -0.28 . . . . 0.0 111.395 177.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -75.42 -29.92 59.88 Favored 'General case' 0 C--N 1.337 0.051 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 177.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 95.5 t -76.87 -41.77 32.55 Favored 'Isoleucine or valine' 0 C--N 1.339 0.116 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 80.9 t -69.81 -29.46 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.1 -29.45 74.45 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.45 -27.25 64.1 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 117.492 0.646 . . . . 0.0 110.757 178.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.55 3.87 23.42 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.406 0.682 . . . . 0.0 111.101 177.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.49 6.37 88.68 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 -177.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.197 0 CA-C-N 117.712 0.756 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.378 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -148.16 -28.85 0.32 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.76 0.424 . . . . 0.0 111.021 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -55.94 -29.23 59.81 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -179.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -62.47 -27.48 69.16 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 177.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 97.1 mt -80.02 -36.88 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.275 0 C-N-CA 123.162 0.585 . . . . 0.0 109.476 176.097 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -66.99 -41.85 87.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 O-C-N 122.418 -0.176 . . . . 0.0 110.886 -178.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.9 mmtp -67.51 -26.99 66.61 Favored 'General case' 0 CA--C 1.527 0.092 0 O-C-N 122.24 -0.287 . . . . 0.0 111.028 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.46 -31.75 63.95 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 117.657 0.208 . . . . 0.0 110.467 178.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 50.8 t -76.19 -37.84 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.098 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.3 t -69.61 -29.0 39.73 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.58 -29.36 74.41 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.4 -26.41 63.68 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.482 0.641 . . . . 0.0 110.226 178.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.4 mt -82.7 4.0 26.81 Favored 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.218 0.607 . . . . 0.0 111.074 178.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.43 6.8 88.95 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 -177.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.136 0 CA-C-N 117.657 0.728 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.064 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -149.94 -30.78 0.22 Allowed 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.853 0.461 . . . . 0.0 110.891 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -55.15 -29.58 58.07 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 117.236 2.309 . . . . 0.0 117.236 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -63.82 -25.81 68.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 178.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt -79.48 -36.1 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 175.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.5 t -66.04 -35.81 75.95 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.085 0 C-N-CA 122.317 0.247 . . . . 0.0 110.987 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.3 mptp? -65.13 -29.01 69.83 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.102 -0.374 . . . . 0.0 110.75 177.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -76.5 -29.73 56.94 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.934 0.334 . . . . 0.0 110.826 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.8 t -73.54 -39.0 53.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 177.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.4 t -70.1 -29.26 39.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 176.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.47 -28.82 73.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.05 -26.67 64.14 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 117.493 0.646 . . . . 0.0 110.601 177.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.3 mt -82.44 3.8 26.76 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.295 0.638 . . . . 0.0 111.072 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 8.03 87.72 Favored Glycine 0 CA--C 1.528 0.862 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.097 0 CA-C-N 117.721 0.761 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.8 tp -153.59 -29.5 0.13 Allowed 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 111.703 0.26 . . . . 0.0 111.703 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . 0.252 27.9 m-85 -57.52 -25.37 59.76 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 117.57 2.434 . . . . 0.0 117.57 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 47.8 t0 -66.21 -29.3 69.53 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 91.8 mt -80.33 -37.73 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.019 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.0 t -63.21 -37.88 80.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 O-C-N 122.349 -0.219 . . . . 0.0 110.84 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm -65.76 -28.8 69.29 Favored 'General case' 0 C--N 1.34 0.153 0 O-C-N 122.194 -0.316 . . . . 0.0 111.236 178.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.47 ' HB2' ' HZ3' ' A' ' 8' ' ' LYS . 4.4 ttmp? -75.25 -31.64 60.86 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 117.751 0.25 . . . . 0.0 110.694 178.054 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t -73.96 -39.09 50.91 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.4 -29.52 39.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.57 -29.08 73.59 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.85 -26.97 64.46 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.369 0.584 . . . . 0.0 110.651 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.3 mt -81.64 3.26 25.97 Favored 'General case' 0 N--CA 1.457 -0.087 0 C-N-CA 123.264 0.626 . . . . 0.0 110.966 177.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 7.14 87.94 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 -177.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.173 0 CA-C-N 117.554 0.677 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.5 mt . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.4 t -65.08 -39.31 85.17 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 O-C-N 122.189 -0.32 . . . . 0.0 110.846 -178.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -66.66 -28.12 68.21 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 122.073 -0.392 . . . . 0.0 111.246 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -74.5 -30.24 61.73 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 117.759 0.254 . . . . 0.0 110.845 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -38.79 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.93 -28.95 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.259 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.8 -29.47 74.86 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.04 -27.29 63.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 117.183 0.491 . . . . 0.0 110.689 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.2 mt -81.13 3.43 23.54 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.113 0.565 . . . . 0.0 111.016 177.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.769 0 N-CA-C 111.884 -0.487 . . . . 0.0 111.884 -177.594 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 70.5 mt . . . . . 0 N--CA 1.452 -0.359 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -69.62 -34.25 60.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 C-N-CA 122.088 0.155 . . . . 0.0 110.868 -179.007 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -62.92 -27.98 69.74 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.72 0.408 . . . . 0.0 111.777 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -78.01 -29.61 49.64 Favored 'General case' 0 C--N 1.338 0.089 0 CA-C-N 117.853 0.297 . . . . 0.0 111.241 176.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.1 t -75.91 -40.6 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.377 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.0 -29.4 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.46 -29.01 73.93 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.439 -0.664 . . . . 0.0 111.439 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.08 -26.72 64.13 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.589 0.694 . . . . 0.0 110.745 177.349 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.6 mt -81.85 3.66 25.23 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.249 0.62 . . . . 0.0 111.173 177.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.887 0 N-CA-C 111.839 -0.504 . . . . 0.0 111.839 -177.682 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 N--CA 1.456 -0.171 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -68.28 -36.03 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.065 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -64.38 -25.59 68.09 Favored 'General case' 0 C--N 1.339 0.139 0 CA-C-N 118.274 0.488 . . . . 0.0 111.656 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -79.87 -29.95 40.1 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.077 0.399 . . . . 0.0 111.127 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.3 t -74.51 -40.77 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.87 -29.41 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.75 72.99 Favored Glycine 0 C--N 1.338 0.654 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 178.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.62 -26.3 63.42 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 117.591 0.695 . . . . 0.0 110.751 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 53.0 mt -82.91 4.82 24.11 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.336 0.654 . . . . 0.0 111.176 177.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.037 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.58 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.7 mt . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.42 -40.64 87.11 Favored 'Isoleucine or valine' 0 C--N 1.34 0.174 0 N-CA-C 110.008 -0.368 . . . . 0.0 110.008 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -67.73 -26.93 66.39 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 122.279 -0.263 . . . . 0.0 111.372 179.443 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -73.1 -32.39 64.94 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 117.832 0.287 . . . . 0.0 110.753 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.2 t -76.61 -38.04 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 63.1 t -70.48 -29.22 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.081 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.94 -28.95 73.51 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.33 -27.01 64.03 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.524 0.662 . . . . 0.0 110.469 177.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.2 mt -82.24 3.73 26.33 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 123.244 0.618 . . . . 0.0 111.108 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.921 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -177.368 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.457 -0.104 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 94.6 t -67.73 -40.84 84.6 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -67.09 -25.83 66.42 Favored 'General case' 0 CA--C 1.529 0.155 0 O-C-N 122.072 -0.392 . . . . 0.0 111.274 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -73.88 -31.57 63.2 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 117.788 0.267 . . . . 0.0 110.632 177.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.9 t -76.02 -38.42 35.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 76.5 t -69.51 -29.52 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.32 -29.12 74.15 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.86 -26.63 63.35 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 117.586 0.693 . . . . 0.0 110.55 177.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.1 mt -81.7 4.79 20.55 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.05 0.54 . . . . 0.0 110.933 177.418 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.879 0 N-CA-C 111.749 -0.54 . . . . 0.0 111.749 -177.969 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.3 mt . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -67.58 -40.17 83.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -66.39 -27.18 67.66 Favored 'General case' 0 C--N 1.338 0.109 0 O-C-N 122.129 -0.357 . . . . 0.0 111.619 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -73.17 -31.06 64.0 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 117.65 0.204 . . . . 0.0 110.701 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -77.03 -38.55 28.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 69.7 t -69.19 -29.1 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.69 -28.96 73.37 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.571 -0.612 . . . . 0.0 111.571 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.12 63.05 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 117.515 0.657 . . . . 0.0 110.554 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.5 mt -83.44 5.16 24.7 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.346 0.658 . . . . 0.0 111.197 177.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.817 0 N-CA-C 111.84 -0.504 . . . . 0.0 111.84 -177.834 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 83.4 mt . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 97.3 t -66.51 -41.28 88.26 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.262 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -67.07 -27.01 67.01 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 122.253 -0.279 . . . . 0.0 111.614 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.3 -32.63 64.73 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 122.271 0.229 . . . . 0.0 110.697 177.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.6 t -75.79 -38.21 36.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 64.4 t -70.17 -28.94 37.7 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.7 -27.89 72.58 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.496 -0.641 . . . . 0.0 111.496 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.54 -26.54 62.69 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 117.479 0.64 . . . . 0.0 110.587 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.1 mt -81.48 3.54 24.38 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.318 0.647 . . . . 0.0 111.082 178.044 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.784 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -177.178 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.452 -0.337 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 90.0 t -64.7 -40.68 89.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.07 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -67.54 -27.75 67.22 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 117.805 0.275 . . . . 0.0 111.173 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -74.28 -31.61 62.59 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 117.931 0.332 . . . . 0.0 111.03 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 47.6 t -74.72 -37.95 43.84 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.6 t -71.85 -29.21 32.73 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.39 -29.49 74.72 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 179.114 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.19 -26.81 65.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 117.295 0.547 . . . . 0.0 110.68 177.349 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.9 mt -82.73 3.77 27.86 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.93 0.492 . . . . 0.0 111.064 178.223 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.822 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.54 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.0 mt . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.96 -42.27 95.21 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.094 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -69.02 -27.15 65.42 Favored 'General case' 0 N--CA 1.457 -0.091 0 O-C-N 122.203 -0.31 . . . . 0.0 110.945 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -71.92 -31.81 66.73 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 122.569 0.348 . . . . 0.0 110.599 177.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 51.3 t -75.49 -36.92 36.49 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.649 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.15 -29.37 39.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.71 -28.19 72.2 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 178.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.61 -27.02 63.76 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 117.239 0.519 . . . . 0.0 110.675 177.061 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -82.72 4.57 24.54 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.261 0.625 . . . . 0.0 111.131 178.217 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.885 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.34 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 93.0 mt . . . . . 0 N--CA 1.457 -0.119 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.4 t -63.18 -35.67 72.87 Favored 'Isoleucine or valine' 0 C--O 1.23 0.073 0 N-CA-C 111.572 0.212 . . . . 0.0 111.572 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -64.67 -27.4 68.9 Favored 'General case' 0 N--CA 1.457 -0.098 0 O-C-N 121.861 -0.525 . . . . 0.0 111.139 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -76.22 -29.82 57.71 Favored 'General case' 0 N--CA 1.461 0.092 0 CA-C-N 117.716 0.234 . . . . 0.0 110.715 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 71.9 t -75.02 -40.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -68.91 -29.32 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.08 -29.51 74.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.79 -0.524 . . . . 0.0 111.79 178.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.06 -27.02 64.29 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.384 0.592 . . . . 0.0 110.857 177.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.0 mt -82.25 3.76 26.21 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.193 0.597 . . . . 0.0 111.099 177.111 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.887 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.892 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 79.3 mt . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 82.6 t -65.75 -41.42 90.29 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -68.82 -27.5 65.9 Favored 'General case' 0 C--N 1.334 -0.103 0 O-C-N 122.356 -0.215 . . . . 0.0 111.363 178.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -71.94 -31.88 66.77 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 122.359 0.263 . . . . 0.0 110.843 177.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.19 -38.12 33.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.206 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.9 t -69.28 -29.27 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 177.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.59 -28.16 72.07 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.07 -26.01 62.0 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 117.515 0.657 . . . . 0.0 110.41 178.137 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -82.48 4.74 23.11 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.219 0.608 . . . . 0.0 111.251 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.818 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -177.969 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 92.4 mt . . . . . 0 CA--C 1.529 0.167 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -62.68 -34.84 67.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 122.157 -0.339 . . . . 0.0 110.725 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.01 -28.19 69.93 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 117.937 0.335 . . . . 0.0 111.413 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.82 -29.67 44.91 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 117.702 0.228 . . . . 0.0 110.731 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.8 t -74.46 -40.05 48.56 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 77.3 t -71.66 -29.0 32.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.06 -29.17 74.13 Favored Glycine 0 C--N 1.339 0.699 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.076 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.2 -26.17 64.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 117.56 0.68 . . . . 0.0 110.763 177.338 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.1 mt -83.21 5.23 23.58 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 123.196 0.599 . . . . 0.0 111.238 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.043 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -177.913 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.4 mt . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.7 -40.35 88.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -66.96 -28.49 68.32 Favored 'General case' 0 N--CA 1.457 -0.093 0 O-C-N 122.075 -0.391 . . . . 0.0 111.227 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.86 -33.7 62.14 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.762 0.255 . . . . 0.0 110.75 178.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 49.8 t -73.41 -39.52 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.131 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -71.2 -29.44 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.01 -29.46 74.95 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.67 -26.1 63.29 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 117.346 0.573 . . . . 0.0 110.751 178.114 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.79 3.31 26.3 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.933 0.493 . . . . 0.0 111.189 177.73 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.924 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -177.695 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.8 mt . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.4 t -63.57 -41.03 91.22 Favored 'Isoleucine or valine' 0 C--O 1.23 0.039 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 178.725 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -70.06 -28.79 65.74 Favored 'General case' 0 C--N 1.34 0.152 0 O-C-N 122.303 -0.248 . . . . 0.0 110.937 177.434 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -71.76 -32.45 67.7 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 122.511 0.324 . . . . 0.0 110.927 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.6 t -73.69 -36.35 46.52 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.5 t -71.04 -29.47 37.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 177.754 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.28 -28.67 73.33 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.82 -25.66 62.95 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.33 0.565 . . . . 0.0 110.867 178.037 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -81.75 3.99 23.67 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 123.069 0.547 . . . . 0.0 111.128 177.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.78 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -177.241 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.9 mt . . . . . 0 N--CA 1.453 -0.277 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 86.0 t -63.83 -40.1 87.81 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -67.46 -28.56 67.98 Favored 'General case' 0 N--CA 1.456 -0.173 0 O-C-N 122.341 -0.224 . . . . 0.0 111.33 177.486 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.57 -32.22 62.33 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.155 0.182 . . . . 0.0 111.029 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 46.8 t -73.38 -38.16 52.81 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.51 -29.19 34.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.53 -28.99 73.3 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.07 -26.75 64.15 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 117.592 0.696 . . . . 0.0 110.421 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.7 mt -82.88 3.91 27.77 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.292 0.637 . . . . 0.0 111.128 177.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.858 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -177.312 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 81.3 mt . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 98.1 t -63.43 -40.49 89.25 Favored 'Isoleucine or valine' 0 C--N 1.339 0.121 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -67.42 -28.52 67.97 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.289 -0.257 . . . . 0.0 111.165 177.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.19 -32.43 63.07 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.709 0.231 . . . . 0.0 110.954 178.102 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.6 t -75.33 -38.08 39.87 Favored 'Isoleucine or valine' 0 C--N 1.338 0.081 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.9 t -70.16 -29.08 38.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 177.627 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.98 -28.76 73.25 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.57 -26.61 63.61 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 117.705 0.753 . . . . 0.0 110.642 177.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.0 mt -82.83 4.34 25.83 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.193 0.597 . . . . 0.0 111.295 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.052 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 -178.044 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.1 mt . . . . . 0 N--CA 1.452 -0.365 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -62.56 -34.16 63.5 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.106 0 O-C-N 122.33 -0.231 . . . . 0.0 110.598 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.86 -26.42 68.6 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 122.253 -0.28 . . . . 0.0 111.395 177.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -75.42 -29.92 59.88 Favored 'General case' 0 C--N 1.337 0.051 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 177.333 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 95.5 t -76.87 -41.77 32.55 Favored 'Isoleucine or valine' 0 C--N 1.339 0.116 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 80.9 t -69.81 -29.46 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.648 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.1 -29.45 74.45 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.45 -27.25 64.1 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 117.492 0.646 . . . . 0.0 110.757 178.115 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.55 3.87 23.42 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.406 0.682 . . . . 0.0 111.101 177.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.013 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 -177.889 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 97.1 mt . . . . . 0 N--CA 1.453 -0.275 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -66.99 -41.85 87.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 O-C-N 122.418 -0.176 . . . . 0.0 110.886 -178.202 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.9 mmtp -67.51 -26.99 66.61 Favored 'General case' 0 CA--C 1.527 0.092 0 O-C-N 122.24 -0.287 . . . . 0.0 111.028 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.46 -31.75 63.95 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 117.657 0.208 . . . . 0.0 110.467 178.076 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 50.8 t -76.19 -37.84 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.098 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.3 t -69.61 -29.0 39.73 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.58 -29.36 74.41 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.4 -26.41 63.68 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.482 0.641 . . . . 0.0 110.226 178.015 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.4 mt -82.7 4.0 26.81 Favored 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.218 0.607 . . . . 0.0 111.074 178.002 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.948 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 -177.442 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 N--CA 1.454 -0.261 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.5 t -66.04 -35.81 75.95 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.085 0 C-N-CA 122.317 0.247 . . . . 0.0 110.987 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.3 mptp? -65.13 -29.01 69.83 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.102 -0.374 . . . . 0.0 110.75 177.601 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -76.5 -29.73 56.94 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.934 0.334 . . . . 0.0 110.826 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.8 t -73.54 -39.0 53.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 177.827 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.4 t -70.1 -29.26 39.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 176.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.47 -28.82 73.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.05 -26.67 64.14 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 117.493 0.646 . . . . 0.0 110.601 177.78 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.3 mt -82.44 3.8 26.76 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.295 0.638 . . . . 0.0 111.072 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.862 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -177.59 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 91.8 mt . . . . . 0 N--CA 1.455 -0.224 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.0 t -63.21 -37.88 80.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 O-C-N 122.349 -0.219 . . . . 0.0 110.84 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm -65.76 -28.8 69.29 Favored 'General case' 0 C--N 1.34 0.153 0 O-C-N 122.194 -0.316 . . . . 0.0 111.236 178.015 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 4.4 ttmp? -75.25 -31.64 60.86 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 117.751 0.25 . . . . 0.0 110.694 178.054 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t -73.96 -39.09 50.91 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.4 -29.52 39.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.57 -29.08 73.59 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.85 -26.97 64.46 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.369 0.584 . . . . 0.0 110.651 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.3 mt -81.64 3.26 25.97 Favored 'General case' 0 N--CA 1.457 -0.087 0 C-N-CA 123.264 0.626 . . . . 0.0 110.966 177.535 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.942 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 -177.68 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.037 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.7 tp -154.96 -29.44 0.11 Allowed 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 122.756 0.422 . . . . 0.0 111.943 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -55.89 -29.09 59.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -63.52 -28.26 69.83 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 120.318 -0.553 . . . . 0.0 111.868 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.5 mt -80.28 -38.77 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 122.907 0.483 . . . . 0.0 109.83 176.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.4 t -65.08 -39.31 85.17 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 O-C-N 122.189 -0.32 . . . . 0.0 110.846 -178.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -66.66 -28.12 68.21 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 122.073 -0.392 . . . . 0.0 111.246 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -74.5 -30.24 61.73 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 117.759 0.254 . . . . 0.0 110.845 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -38.79 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.93 -28.95 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.259 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.8 -29.47 74.86 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.04 -27.29 63.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 117.183 0.491 . . . . 0.0 110.689 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.2 mt -81.13 3.43 23.54 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.113 0.565 . . . . 0.0 111.016 177.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.16 7.01 88.32 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.884 -0.487 . . . . 0.0 111.884 -177.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.131 0 CA-C-N 117.961 0.881 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.056 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 63.8 tp -153.64 -28.13 0.13 Allowed 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 122.66 0.384 . . . . 0.0 111.897 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -54.05 -35.54 62.1 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 116.658 2.096 . . . . 0.0 116.658 -178.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -66.48 -22.68 66.19 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 70.5 mt -80.73 -41.4 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 174.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -69.62 -34.25 60.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 C-N-CA 122.088 0.155 . . . . 0.0 110.868 -179.007 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -62.92 -27.98 69.74 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.72 0.408 . . . . 0.0 111.777 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -78.01 -29.61 49.64 Favored 'General case' 0 C--N 1.338 0.089 0 CA-C-N 117.853 0.297 . . . . 0.0 111.241 176.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.1 t -75.91 -40.6 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.377 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.0 -29.4 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.46 -29.01 73.93 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.439 -0.664 . . . . 0.0 111.439 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.08 -26.72 64.13 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.589 0.694 . . . . 0.0 110.745 177.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.6 mt -81.85 3.66 25.23 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.249 0.62 . . . . 0.0 111.173 177.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.83 8.45 86.73 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.839 -0.504 . . . . 0.0 111.839 -177.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.17 0 CA-C-N 117.856 0.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.043 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.4 tp -153.18 -29.37 0.14 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.742 0.417 . . . . 0.0 111.762 -179.635 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -55.38 -31.19 61.6 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -65.0 -25.14 67.73 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt -82.52 -42.57 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 C-N-CA 122.682 0.393 . . . . 0.0 110.201 174.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -68.28 -36.03 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.065 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -64.38 -25.59 68.09 Favored 'General case' 0 C--N 1.339 0.139 0 CA-C-N 118.274 0.488 . . . . 0.0 111.656 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -79.87 -29.95 40.1 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.077 0.399 . . . . 0.0 111.127 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.3 t -74.51 -40.77 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.87 -29.41 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.75 72.99 Favored Glycine 0 C--N 1.338 0.654 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 178.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.62 -26.3 63.42 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 117.591 0.695 . . . . 0.0 110.751 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 53.0 mt -82.91 4.82 24.11 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.336 0.654 . . . . 0.0 111.176 177.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 6.59 88.58 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.153 0 CA-C-N 117.886 0.843 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.926 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.3 tp -152.25 -28.03 0.17 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.549 0.34 . . . . 0.0 111.688 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.7 m-85 -56.5 -29.55 61.95 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 116.644 2.09 . . . . 0.0 116.644 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -66.5 -28.66 68.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.651 -0.42 . . . . 0.0 112.004 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.7 mt -80.17 -39.91 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 C-N-CA 122.777 0.431 . . . . 0.0 110.014 177.383 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.42 -40.64 87.11 Favored 'Isoleucine or valine' 0 C--N 1.34 0.174 0 N-CA-C 110.008 -0.368 . . . . 0.0 110.008 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -67.73 -26.93 66.39 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 122.279 -0.263 . . . . 0.0 111.372 179.443 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -73.1 -32.39 64.94 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 117.832 0.287 . . . . 0.0 110.753 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.2 t -76.61 -38.04 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 63.1 t -70.48 -29.22 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.081 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.94 -28.95 73.51 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.33 -27.01 64.03 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.524 0.662 . . . . 0.0 110.469 177.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.2 mt -82.24 3.73 26.33 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 123.244 0.618 . . . . 0.0 111.108 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.42 7.65 88.03 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.061 0 CA-C-N 117.764 0.782 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.114 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 61.5 tp -82.4 -25.94 33.26 Favored 'General case' 0 CA--C 1.524 -0.034 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -56.37 -29.54 61.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -67.88 -29.05 68.06 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.56 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.3 mt -80.07 -39.18 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 94.6 t -67.73 -40.84 84.6 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -67.09 -25.83 66.42 Favored 'General case' 0 CA--C 1.529 0.155 0 O-C-N 122.072 -0.392 . . . . 0.0 111.274 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -73.88 -31.57 63.2 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 117.788 0.267 . . . . 0.0 110.632 177.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.9 t -76.02 -38.42 35.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 76.5 t -69.51 -29.52 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.32 -29.12 74.15 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.86 -26.63 63.35 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 117.586 0.693 . . . . 0.0 110.55 177.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.1 mt -81.7 4.79 20.55 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.05 0.54 . . . . 0.0 110.933 177.418 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 7.88 87.88 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.749 -0.54 . . . . 0.0 111.749 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.137 0 CA-C-N 117.836 0.818 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.042 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.8 tp -152.95 -28.32 0.15 Allowed 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.662 0.385 . . . . 0.0 111.421 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -56.28 -29.31 61.0 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 116.762 2.134 . . . . 0.0 116.762 -179.293 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -66.75 -28.42 68.4 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 178.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.3 mt -80.63 -39.51 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 122.803 0.441 . . . . 0.0 109.907 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -67.58 -40.17 83.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -66.39 -27.18 67.66 Favored 'General case' 0 C--N 1.338 0.109 0 O-C-N 122.129 -0.357 . . . . 0.0 111.619 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -73.17 -31.06 64.0 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 117.65 0.204 . . . . 0.0 110.701 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -77.03 -38.55 28.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 69.7 t -69.19 -29.1 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.69 -28.96 73.37 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.571 -0.612 . . . . 0.0 111.571 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.12 63.05 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 117.515 0.657 . . . . 0.0 110.554 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.5 mt -83.44 5.16 24.7 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.346 0.658 . . . . 0.0 111.197 177.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.94 6.39 88.42 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.84 -0.504 . . . . 0.0 111.84 -177.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.098 0 CA-C-N 117.785 0.793 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.096 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.0 tp -154.12 -27.5 0.13 Allowed 'General case' 0 C--O 1.232 0.168 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -56.72 -29.53 62.58 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 116.894 2.183 . . . . 0.0 116.894 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -66.81 -28.87 68.72 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.048 178.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 83.4 mt -80.04 -39.65 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.086 0.554 . . . . 0.0 109.804 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 97.3 t -66.51 -41.28 88.26 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.262 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -67.07 -27.01 67.01 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 122.253 -0.279 . . . . 0.0 111.614 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.3 -32.63 64.73 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 122.271 0.229 . . . . 0.0 110.697 177.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.6 t -75.79 -38.21 36.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 64.4 t -70.17 -28.94 37.7 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.7 -27.89 72.58 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.496 -0.641 . . . . 0.0 111.496 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.54 -26.54 62.69 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 117.479 0.64 . . . . 0.0 110.587 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.1 mt -81.48 3.54 24.38 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.318 0.647 . . . . 0.0 111.082 178.044 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.17 7.02 88.31 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -177.178 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.018 0 O-C-N 121.772 -0.84 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.056 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 60.8 tp -83.87 -25.6 30.11 Favored 'General case' 0 C--N 1.334 -0.103 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -56.87 -29.37 62.86 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 116.494 2.035 . . . . 0.0 116.494 -178.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -66.78 -29.21 69.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.732 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -79.82 -36.55 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 C-N-CA 122.826 0.45 . . . . 0.0 109.899 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 90.0 t -64.7 -40.68 89.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.07 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -67.54 -27.75 67.22 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 117.805 0.275 . . . . 0.0 111.173 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -74.28 -31.61 62.59 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 117.931 0.332 . . . . 0.0 111.03 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 47.6 t -74.72 -37.95 43.84 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.6 t -71.85 -29.21 32.73 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.39 -29.49 74.72 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 179.114 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.19 -26.81 65.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 117.295 0.547 . . . . 0.0 110.68 177.349 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.9 mt -82.73 3.77 27.86 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.93 0.492 . . . . 0.0 111.064 178.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 6.54 88.69 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.066 0 CA-C-N 117.632 0.716 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.012 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 68.0 tp -154.94 -29.24 0.11 Allowed 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 122.687 0.395 . . . . 0.0 111.722 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -55.63 -29.12 58.65 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 117.256 2.317 . . . . 0.0 117.256 -178.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -63.76 -29.07 70.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 120.051 -0.66 . . . . 0.0 111.59 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.0 mt -80.64 -37.23 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 123.141 0.576 . . . . 0.0 109.78 176.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.96 -42.27 95.21 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.094 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -69.02 -27.15 65.42 Favored 'General case' 0 N--CA 1.457 -0.091 0 O-C-N 122.203 -0.31 . . . . 0.0 110.945 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -71.92 -31.81 66.73 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 122.569 0.348 . . . . 0.0 110.599 177.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 51.3 t -75.49 -36.92 36.49 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.649 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.15 -29.37 39.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.71 -28.19 72.2 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 178.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.61 -27.02 63.76 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 117.239 0.519 . . . . 0.0 110.675 177.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -82.72 4.57 24.54 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.261 0.625 . . . . 0.0 111.131 178.217 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.92 6.05 89.27 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.34 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.115 0 CA-C-N 117.798 0.799 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.083 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.6 tp -154.86 -30.32 0.11 Allowed 'General case' 0 CA--C 1.528 0.111 0 C-N-CA 122.555 0.342 . . . . 0.0 111.634 179.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . 0.259 30.7 m-85 -55.26 -29.08 57.39 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 117.309 2.337 . . . . 0.0 117.309 -178.127 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -62.65 -28.61 70.04 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 120.517 -0.473 . . . . 0.0 111.667 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 93.0 mt -80.89 -38.31 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 C-N-CA 123.141 0.577 . . . . 0.0 110.005 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.4 t -63.18 -35.67 72.87 Favored 'Isoleucine or valine' 0 C--O 1.23 0.073 0 N-CA-C 111.572 0.212 . . . . 0.0 111.572 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -64.67 -27.4 68.9 Favored 'General case' 0 N--CA 1.457 -0.098 0 O-C-N 121.861 -0.525 . . . . 0.0 111.139 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -76.22 -29.82 57.71 Favored 'General case' 0 N--CA 1.461 0.092 0 CA-C-N 117.716 0.234 . . . . 0.0 110.715 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 71.9 t -75.02 -40.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -68.91 -29.32 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.08 -29.51 74.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.79 -0.524 . . . . 0.0 111.79 178.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.06 -27.02 64.29 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.384 0.592 . . . . 0.0 110.857 177.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.0 mt -82.25 3.76 26.21 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.193 0.597 . . . . 0.0 111.099 177.111 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.97 6.21 89.11 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.134 0 CA-C-N 117.671 0.736 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.041 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.6 tp -152.68 -28.73 0.15 Allowed 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 122.814 0.446 . . . . 0.0 111.868 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -55.94 -29.63 60.42 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 117.03 2.233 . . . . 0.0 117.03 -179.065 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -67.05 -29.35 69.11 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.126 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 79.3 mt -80.23 -38.45 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 C-N-CA 122.786 0.434 . . . . 0.0 109.906 177.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 82.6 t -65.75 -41.42 90.29 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -68.82 -27.5 65.9 Favored 'General case' 0 C--N 1.334 -0.103 0 O-C-N 122.356 -0.215 . . . . 0.0 111.363 178.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -71.94 -31.88 66.77 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 122.359 0.263 . . . . 0.0 110.843 177.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.19 -38.12 33.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.206 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.9 t -69.28 -29.27 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 177.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.59 -28.16 72.07 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.07 -26.01 62.0 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 117.515 0.657 . . . . 0.0 110.41 178.137 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -82.48 4.74 23.11 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.219 0.608 . . . . 0.0 111.251 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.26 7.36 87.79 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.084 0 CA-C-N 118.017 0.909 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.021 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.3 tp -154.52 -30.47 0.11 Allowed 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 122.563 0.345 . . . . 0.0 111.854 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -55.87 -29.37 59.82 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 116.67 2.1 . . . . 0.0 116.67 -177.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -63.32 -28.4 69.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 120.479 -0.489 . . . . 0.0 111.823 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 92.4 mt -80.06 -36.83 17.12 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -62.68 -34.84 67.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 122.157 -0.339 . . . . 0.0 110.725 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.01 -28.19 69.93 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 117.937 0.335 . . . . 0.0 111.413 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.82 -29.67 44.91 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 117.702 0.228 . . . . 0.0 110.731 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.8 t -74.46 -40.05 48.56 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 77.3 t -71.66 -29.0 32.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.06 -29.17 74.13 Favored Glycine 0 C--N 1.339 0.699 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.076 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.2 -26.17 64.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 117.56 0.68 . . . . 0.0 110.763 177.338 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.1 mt -83.21 5.23 23.58 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 123.196 0.599 . . . . 0.0 111.238 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 6.12 89.05 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -177.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.133 0 CA-C-N 117.757 0.778 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.012 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.8 tp -154.34 -29.4 0.12 Allowed 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 122.466 0.307 . . . . 0.0 111.73 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -56.08 -29.12 60.11 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 116.88 2.178 . . . . 0.0 116.88 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -65.58 -28.05 68.86 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.959 178.014 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.4 mt -80.02 -37.31 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 175.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.7 -40.35 88.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -66.96 -28.49 68.32 Favored 'General case' 0 N--CA 1.457 -0.093 0 O-C-N 122.075 -0.391 . . . . 0.0 111.227 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.86 -33.7 62.14 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.762 0.255 . . . . 0.0 110.75 178.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 49.8 t -73.41 -39.52 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.131 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -71.2 -29.44 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.01 -29.46 74.95 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.67 -26.1 63.29 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 117.346 0.573 . . . . 0.0 110.751 178.114 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.79 3.31 26.3 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.933 0.493 . . . . 0.0 111.189 177.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.94 8.79 86.2 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -177.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.029 0 CA-C-N 117.688 0.744 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.027 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.6 tp -153.71 -28.05 0.13 Allowed 'General case' 0 CA--C 1.527 0.077 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -56.54 -29.44 61.95 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 116.736 2.125 . . . . 0.0 116.736 -178.2 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -65.57 -28.71 69.34 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 120.443 -0.503 . . . . 0.0 112.051 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.8 mt -80.47 -35.16 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 C-N-CA 123.003 0.521 . . . . 0.0 110.045 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.4 t -63.57 -41.03 91.22 Favored 'Isoleucine or valine' 0 C--O 1.23 0.039 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 178.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -70.06 -28.79 65.74 Favored 'General case' 0 C--N 1.34 0.152 0 O-C-N 122.303 -0.248 . . . . 0.0 110.937 177.434 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -71.76 -32.45 67.7 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 122.511 0.324 . . . . 0.0 110.927 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.6 t -73.69 -36.35 46.52 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.5 t -71.04 -29.47 37.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 177.754 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.28 -28.67 73.33 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.82 -25.66 62.95 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.33 0.565 . . . . 0.0 110.867 178.037 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -81.75 3.99 23.67 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 123.069 0.547 . . . . 0.0 111.128 177.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.97 7.13 88.29 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -177.241 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.104 0 CA-C-N 118.054 0.927 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.921 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 68.4 tp -154.18 -28.64 0.12 Allowed 'General case' 0 CA--C 1.528 0.112 0 C-N-CA 122.466 0.306 . . . . 0.0 111.666 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -56.12 -29.14 60.24 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 117.218 2.303 . . . . 0.0 117.218 -178.227 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -65.38 -28.36 69.22 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.786 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.9 mt -79.91 -36.74 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 176.4 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 86.0 t -63.83 -40.1 87.81 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -67.46 -28.56 67.98 Favored 'General case' 0 N--CA 1.456 -0.173 0 O-C-N 122.341 -0.224 . . . . 0.0 111.33 177.486 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.57 -32.22 62.33 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.155 0.182 . . . . 0.0 111.029 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 46.8 t -73.38 -38.16 52.81 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.51 -29.19 34.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.53 -28.99 73.3 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.07 -26.75 64.15 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 117.592 0.696 . . . . 0.0 110.421 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.7 mt -82.88 3.91 27.77 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.292 0.637 . . . . 0.0 111.128 177.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.5 6.74 88.96 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -177.312 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.042 0 CA-C-N 117.595 0.698 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.073 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.5 tp -154.11 -28.48 0.12 Allowed 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.7 m-85 -56.16 -29.29 60.59 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 117.064 2.246 . . . . 0.0 117.064 -178.103 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -65.98 -28.1 68.63 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.51 -0.476 . . . . 0.0 112.114 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 81.3 mt -80.04 -37.35 17.63 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 176.364 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 98.1 t -63.43 -40.49 89.25 Favored 'Isoleucine or valine' 0 C--N 1.339 0.121 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -67.42 -28.52 67.97 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.289 -0.257 . . . . 0.0 111.165 177.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.19 -32.43 63.07 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.709 0.231 . . . . 0.0 110.954 178.102 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.6 t -75.33 -38.08 39.87 Favored 'Isoleucine or valine' 0 C--N 1.338 0.081 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.9 t -70.16 -29.08 38.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 177.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.98 -28.76 73.25 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.57 -26.61 63.61 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 117.705 0.753 . . . . 0.0 110.642 177.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.0 mt -82.83 4.34 25.83 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.193 0.597 . . . . 0.0 111.295 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.27 6.73 88.49 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 -178.044 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.12 0 CA-C-N 117.807 0.804 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.86 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.9 tp -154.93 -30.32 0.1 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 122.698 -0.295 . . . . 0.0 111.73 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -55.72 -29.64 59.81 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 116.919 2.192 . . . . 0.0 116.919 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -63.21 -27.63 69.49 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.153 177.729 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.1 mt -80.6 -36.6 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 C-N-CA 123.177 0.591 . . . . 0.0 109.944 175.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -62.56 -34.16 63.5 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.106 0 O-C-N 122.33 -0.231 . . . . 0.0 110.598 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.86 -26.42 68.6 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 122.253 -0.28 . . . . 0.0 111.395 177.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -75.42 -29.92 59.88 Favored 'General case' 0 C--N 1.337 0.051 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 177.333 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 95.5 t -76.87 -41.77 32.55 Favored 'Isoleucine or valine' 0 C--N 1.339 0.116 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 80.9 t -69.81 -29.46 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.648 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.1 -29.45 74.45 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.45 -27.25 64.1 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 117.492 0.646 . . . . 0.0 110.757 178.115 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.55 3.87 23.42 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.406 0.682 . . . . 0.0 111.101 177.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.49 6.37 88.68 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 -177.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.197 0 CA-C-N 117.712 0.756 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.378 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -148.16 -28.85 0.32 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.76 0.424 . . . . 0.0 111.021 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -55.94 -29.23 59.81 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -179.42 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -62.47 -27.48 69.16 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 177.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 97.1 mt -80.02 -36.88 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.275 0 C-N-CA 123.162 0.585 . . . . 0.0 109.476 176.097 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -66.99 -41.85 87.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 O-C-N 122.418 -0.176 . . . . 0.0 110.886 -178.202 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.9 mmtp -67.51 -26.99 66.61 Favored 'General case' 0 CA--C 1.527 0.092 0 O-C-N 122.24 -0.287 . . . . 0.0 111.028 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.46 -31.75 63.95 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 117.657 0.208 . . . . 0.0 110.467 178.076 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 50.8 t -76.19 -37.84 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.098 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.3 t -69.61 -29.0 39.73 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.58 -29.36 74.41 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.4 -26.41 63.68 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.482 0.641 . . . . 0.0 110.226 178.015 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.4 mt -82.7 4.0 26.81 Favored 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.218 0.607 . . . . 0.0 111.074 178.002 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.43 6.8 88.95 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 -177.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.136 0 CA-C-N 117.657 0.728 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.064 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -149.94 -30.78 0.22 Allowed 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.853 0.461 . . . . 0.0 110.891 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -55.15 -29.58 58.07 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 117.236 2.309 . . . . 0.0 117.236 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -63.82 -25.81 68.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 178.628 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt -79.48 -36.1 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 175.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.5 t -66.04 -35.81 75.95 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.085 0 C-N-CA 122.317 0.247 . . . . 0.0 110.987 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.3 mptp? -65.13 -29.01 69.83 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.102 -0.374 . . . . 0.0 110.75 177.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -76.5 -29.73 56.94 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.934 0.334 . . . . 0.0 110.826 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.8 t -73.54 -39.0 53.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 177.827 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.4 t -70.1 -29.26 39.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 176.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.47 -28.82 73.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.05 -26.67 64.14 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 117.493 0.646 . . . . 0.0 110.601 177.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.3 mt -82.44 3.8 26.76 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.295 0.638 . . . . 0.0 111.072 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 8.03 87.72 Favored Glycine 0 CA--C 1.528 0.862 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.097 0 CA-C-N 117.721 0.761 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.8 tp -153.59 -29.5 0.13 Allowed 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 111.703 0.26 . . . . 0.0 111.703 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . 0.252 27.9 m-85 -57.52 -25.37 59.76 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 117.57 2.434 . . . . 0.0 117.57 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 47.8 t0 -66.21 -29.3 69.53 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 91.8 mt -80.33 -37.73 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.019 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.0 t -63.21 -37.88 80.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 O-C-N 122.349 -0.219 . . . . 0.0 110.84 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm -65.76 -28.8 69.29 Favored 'General case' 0 C--N 1.34 0.153 0 O-C-N 122.194 -0.316 . . . . 0.0 111.236 178.015 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 4.4 ttmp? -75.25 -31.64 60.86 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 117.751 0.25 . . . . 0.0 110.694 178.054 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t -73.96 -39.09 50.91 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.4 -29.52 39.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.57 -29.08 73.59 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.85 -26.97 64.46 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.369 0.584 . . . . 0.0 110.651 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.3 mt -81.64 3.26 25.97 Favored 'General case' 0 N--CA 1.457 -0.087 0 C-N-CA 123.264 0.626 . . . . 0.0 110.966 177.535 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 7.14 87.94 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 -177.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.173 0 CA-C-N 117.554 0.677 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.5 mt . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.4 t -65.08 -39.31 85.17 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 O-C-N 122.189 -0.32 . . . . 0.0 110.846 -178.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -66.66 -28.12 68.21 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 122.073 -0.392 . . . . 0.0 111.246 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -74.5 -30.24 61.73 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 117.759 0.254 . . . . 0.0 110.845 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -38.79 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.93 -28.95 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.8 -29.47 74.86 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.04 -27.29 63.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 117.183 0.491 . . . . 0.0 110.689 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.2 mt -81.13 3.43 23.54 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.113 0.565 . . . . 0.0 111.016 177.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.769 0 N-CA-C 111.884 -0.487 . . . . 0.0 111.884 -177.594 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 70.5 mt . . . . . 0 N--CA 1.452 -0.359 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -69.62 -34.25 60.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 C-N-CA 122.088 0.155 . . . . 0.0 110.868 -179.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -62.92 -27.98 69.74 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.72 0.408 . . . . 0.0 111.777 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -78.01 -29.61 49.64 Favored 'General case' 0 C--N 1.338 0.089 0 CA-C-N 117.853 0.297 . . . . 0.0 111.241 176.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.1 t -75.91 -40.6 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.0 -29.4 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.46 -29.01 73.93 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.439 -0.664 . . . . 0.0 111.439 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.08 -26.72 64.13 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.589 0.694 . . . . 0.0 110.745 177.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.6 mt -81.85 3.66 25.23 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.249 0.62 . . . . 0.0 111.173 177.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.887 0 N-CA-C 111.839 -0.504 . . . . 0.0 111.839 -177.682 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 N--CA 1.456 -0.171 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -68.28 -36.03 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.065 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -64.38 -25.59 68.09 Favored 'General case' 0 C--N 1.339 0.139 0 CA-C-N 118.274 0.488 . . . . 0.0 111.656 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -79.87 -29.95 40.1 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.077 0.399 . . . . 0.0 111.127 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.3 t -74.51 -40.77 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.87 -29.41 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.75 72.99 Favored Glycine 0 C--N 1.338 0.654 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 178.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.62 -26.3 63.42 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 117.591 0.695 . . . . 0.0 110.751 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 53.0 mt -82.91 4.82 24.11 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.336 0.654 . . . . 0.0 111.176 177.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.037 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.58 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.7 mt . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.42 -40.64 87.11 Favored 'Isoleucine or valine' 0 C--N 1.34 0.174 0 N-CA-C 110.008 -0.368 . . . . 0.0 110.008 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -67.73 -26.93 66.39 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 122.279 -0.263 . . . . 0.0 111.372 179.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -73.1 -32.39 64.94 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 117.832 0.287 . . . . 0.0 110.753 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.2 t -76.61 -38.04 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 63.1 t -70.48 -29.22 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.94 -28.95 73.51 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.33 -27.01 64.03 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.524 0.662 . . . . 0.0 110.469 177.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.2 mt -82.24 3.73 26.33 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 123.244 0.618 . . . . 0.0 111.108 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.921 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -177.368 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.457 -0.104 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 94.6 t -67.73 -40.84 84.6 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -67.09 -25.83 66.42 Favored 'General case' 0 CA--C 1.529 0.155 0 O-C-N 122.072 -0.392 . . . . 0.0 111.274 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -73.88 -31.57 63.2 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 117.788 0.267 . . . . 0.0 110.632 177.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.9 t -76.02 -38.42 35.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 76.5 t -69.51 -29.52 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.32 -29.12 74.15 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.86 -26.63 63.35 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 117.586 0.693 . . . . 0.0 110.55 177.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.1 mt -81.7 4.79 20.55 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.05 0.54 . . . . 0.0 110.933 177.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.879 0 N-CA-C 111.749 -0.54 . . . . 0.0 111.749 -177.969 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.3 mt . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -67.58 -40.17 83.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -66.39 -27.18 67.66 Favored 'General case' 0 C--N 1.338 0.109 0 O-C-N 122.129 -0.357 . . . . 0.0 111.619 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -73.17 -31.06 64.0 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 117.65 0.204 . . . . 0.0 110.701 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -77.03 -38.55 28.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 69.7 t -69.19 -29.1 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.69 -28.96 73.37 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.571 -0.612 . . . . 0.0 111.571 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.12 63.05 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 117.515 0.657 . . . . 0.0 110.554 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.5 mt -83.44 5.16 24.7 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.346 0.658 . . . . 0.0 111.197 177.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.817 0 N-CA-C 111.84 -0.504 . . . . 0.0 111.84 -177.834 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 83.4 mt . . . . . 0 N--CA 1.454 -0.27 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 97.3 t -66.51 -41.28 88.26 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -67.07 -27.01 67.01 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 122.253 -0.279 . . . . 0.0 111.614 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.3 -32.63 64.73 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 122.271 0.229 . . . . 0.0 110.697 177.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.6 t -75.79 -38.21 36.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 64.4 t -70.17 -28.94 37.7 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.7 -27.89 72.58 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.496 -0.641 . . . . 0.0 111.496 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.54 -26.54 62.69 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 117.479 0.64 . . . . 0.0 110.587 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.1 mt -81.48 3.54 24.38 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.318 0.647 . . . . 0.0 111.082 178.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.784 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -177.178 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 N--CA 1.452 -0.337 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 90.0 t -64.7 -40.68 89.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.07 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -67.54 -27.75 67.22 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 117.805 0.275 . . . . 0.0 111.173 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -74.28 -31.61 62.59 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 117.931 0.332 . . . . 0.0 111.03 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 47.6 t -74.72 -37.95 43.84 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.6 t -71.85 -29.21 32.73 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.39 -29.49 74.72 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 179.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.19 -26.81 65.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 117.295 0.547 . . . . 0.0 110.68 177.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.9 mt -82.73 3.77 27.86 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.93 0.492 . . . . 0.0 111.064 178.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.822 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.54 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.0 mt . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.96 -42.27 95.21 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.094 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -69.02 -27.15 65.42 Favored 'General case' 0 N--CA 1.457 -0.091 0 O-C-N 122.203 -0.31 . . . . 0.0 110.945 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -71.92 -31.81 66.73 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 122.569 0.348 . . . . 0.0 110.599 177.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 51.3 t -75.49 -36.92 36.49 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.15 -29.37 39.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.71 -28.19 72.2 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 178.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.61 -27.02 63.76 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 117.239 0.519 . . . . 0.0 110.675 177.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -82.72 4.57 24.54 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.261 0.625 . . . . 0.0 111.131 178.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.885 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.34 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 93.0 mt . . . . . 0 N--CA 1.457 -0.119 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.4 t -63.18 -35.67 72.87 Favored 'Isoleucine or valine' 0 C--O 1.23 0.073 0 N-CA-C 111.572 0.212 . . . . 0.0 111.572 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -64.67 -27.4 68.9 Favored 'General case' 0 N--CA 1.457 -0.098 0 O-C-N 121.861 -0.525 . . . . 0.0 111.139 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -76.22 -29.82 57.71 Favored 'General case' 0 N--CA 1.461 0.092 0 CA-C-N 117.716 0.234 . . . . 0.0 110.715 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 71.9 t -75.02 -40.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -68.91 -29.32 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.08 -29.51 74.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.79 -0.524 . . . . 0.0 111.79 178.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.06 -27.02 64.29 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.384 0.592 . . . . 0.0 110.857 177.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.0 mt -82.25 3.76 26.21 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.193 0.597 . . . . 0.0 111.099 177.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.887 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.892 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 79.3 mt . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 82.6 t -65.75 -41.42 90.29 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -68.82 -27.5 65.9 Favored 'General case' 0 C--N 1.334 -0.103 0 O-C-N 122.356 -0.215 . . . . 0.0 111.363 178.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -71.94 -31.88 66.77 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 122.359 0.263 . . . . 0.0 110.843 177.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.19 -38.12 33.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.9 t -69.28 -29.27 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 177.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.59 -28.16 72.07 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.07 -26.01 62.0 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 117.515 0.657 . . . . 0.0 110.41 178.137 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -82.48 4.74 23.11 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.219 0.608 . . . . 0.0 111.251 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.818 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -177.969 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 92.4 mt . . . . . 0 CA--C 1.529 0.167 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -62.68 -34.84 67.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 122.157 -0.339 . . . . 0.0 110.725 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.01 -28.19 69.93 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 117.937 0.335 . . . . 0.0 111.413 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.82 -29.67 44.91 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 117.702 0.228 . . . . 0.0 110.731 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.8 t -74.46 -40.05 48.56 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 77.3 t -71.66 -29.0 32.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.06 -29.17 74.13 Favored Glycine 0 C--N 1.339 0.699 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.2 -26.17 64.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 117.56 0.68 . . . . 0.0 110.763 177.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.1 mt -83.21 5.23 23.58 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 123.196 0.599 . . . . 0.0 111.238 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.043 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -177.913 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.4 mt . . . . . 0 N--CA 1.452 -0.333 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.7 -40.35 88.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -66.96 -28.49 68.32 Favored 'General case' 0 N--CA 1.457 -0.093 0 O-C-N 122.075 -0.391 . . . . 0.0 111.227 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.86 -33.7 62.14 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.762 0.255 . . . . 0.0 110.75 178.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 49.8 t -73.41 -39.52 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.131 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -71.2 -29.44 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.01 -29.46 74.95 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.67 -26.1 63.29 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 117.346 0.573 . . . . 0.0 110.751 178.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.79 3.31 26.3 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.933 0.493 . . . . 0.0 111.189 177.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.924 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -177.695 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.8 mt . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.4 t -63.57 -41.03 91.22 Favored 'Isoleucine or valine' 0 C--O 1.23 0.039 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 178.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -70.06 -28.79 65.74 Favored 'General case' 0 C--N 1.34 0.152 0 O-C-N 122.303 -0.248 . . . . 0.0 110.937 177.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -71.76 -32.45 67.7 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 122.511 0.324 . . . . 0.0 110.927 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.6 t -73.69 -36.35 46.52 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.5 t -71.04 -29.47 37.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 177.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.28 -28.67 73.33 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.82 -25.66 62.95 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.33 0.565 . . . . 0.0 110.867 178.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -81.75 3.99 23.67 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 123.069 0.547 . . . . 0.0 111.128 177.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.78 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -177.241 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.9 mt . . . . . 0 N--CA 1.453 -0.277 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 86.0 t -63.83 -40.1 87.81 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -67.46 -28.56 67.98 Favored 'General case' 0 N--CA 1.456 -0.173 0 O-C-N 122.341 -0.224 . . . . 0.0 111.33 177.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.57 -32.22 62.33 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.155 0.182 . . . . 0.0 111.029 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 46.8 t -73.38 -38.16 52.81 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.51 -29.19 34.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.53 -28.99 73.3 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.07 -26.75 64.15 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 117.592 0.696 . . . . 0.0 110.421 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.7 mt -82.88 3.91 27.77 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.292 0.637 . . . . 0.0 111.128 177.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.858 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -177.312 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 81.3 mt . . . . . 0 CA--C 1.532 0.263 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 98.1 t -63.43 -40.49 89.25 Favored 'Isoleucine or valine' 0 C--N 1.339 0.121 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -67.42 -28.52 67.97 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.289 -0.257 . . . . 0.0 111.165 177.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.19 -32.43 63.07 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.709 0.231 . . . . 0.0 110.954 178.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.6 t -75.33 -38.08 39.87 Favored 'Isoleucine or valine' 0 C--N 1.338 0.081 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.9 t -70.16 -29.08 38.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 177.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.98 -28.76 73.25 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.57 -26.61 63.61 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 117.705 0.753 . . . . 0.0 110.642 177.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.0 mt -82.83 4.34 25.83 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.193 0.597 . . . . 0.0 111.295 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.052 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 -178.044 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.1 mt . . . . . 0 N--CA 1.452 -0.365 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -62.56 -34.16 63.5 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.106 0 O-C-N 122.33 -0.231 . . . . 0.0 110.598 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.86 -26.42 68.6 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 122.253 -0.28 . . . . 0.0 111.395 177.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -75.42 -29.92 59.88 Favored 'General case' 0 C--N 1.337 0.051 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 177.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 95.5 t -76.87 -41.77 32.55 Favored 'Isoleucine or valine' 0 C--N 1.339 0.116 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 80.9 t -69.81 -29.46 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.1 -29.45 74.45 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.45 -27.25 64.1 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 117.492 0.646 . . . . 0.0 110.757 178.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.55 3.87 23.42 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.406 0.682 . . . . 0.0 111.101 177.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.013 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 -177.889 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 97.1 mt . . . . . 0 N--CA 1.453 -0.275 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -66.99 -41.85 87.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 O-C-N 122.418 -0.176 . . . . 0.0 110.886 -178.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.9 mmtp -67.51 -26.99 66.61 Favored 'General case' 0 CA--C 1.527 0.092 0 O-C-N 122.24 -0.287 . . . . 0.0 111.028 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.46 -31.75 63.95 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 117.657 0.208 . . . . 0.0 110.467 178.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 50.8 t -76.19 -37.84 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.098 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.3 t -69.61 -29.0 39.73 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.58 -29.36 74.41 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.4 -26.41 63.68 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.482 0.641 . . . . 0.0 110.226 178.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.4 mt -82.7 4.0 26.81 Favored 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.218 0.607 . . . . 0.0 111.074 178.002 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.948 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 -177.442 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt . . . . . 0 N--CA 1.454 -0.261 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.5 t -66.04 -35.81 75.95 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.085 0 C-N-CA 122.317 0.247 . . . . 0.0 110.987 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.3 mptp? -65.13 -29.01 69.83 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.102 -0.374 . . . . 0.0 110.75 177.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -76.5 -29.73 56.94 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.934 0.334 . . . . 0.0 110.826 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.8 t -73.54 -39.0 53.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 177.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.4 t -70.1 -29.26 39.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 176.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.47 -28.82 73.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.05 -26.67 64.14 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 117.493 0.646 . . . . 0.0 110.601 177.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.3 mt -82.44 3.8 26.76 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.295 0.638 . . . . 0.0 111.072 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.862 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -177.59 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 91.8 mt . . . . . 0 N--CA 1.455 -0.224 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.0 t -63.21 -37.88 80.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 O-C-N 122.349 -0.219 . . . . 0.0 110.84 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm -65.76 -28.8 69.29 Favored 'General case' 0 C--N 1.34 0.153 0 O-C-N 122.194 -0.316 . . . . 0.0 111.236 178.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 4.4 ttmp? -75.25 -31.64 60.86 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 117.751 0.25 . . . . 0.0 110.694 178.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t -73.96 -39.09 50.91 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.4 -29.52 39.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.57 -29.08 73.59 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.85 -26.97 64.46 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.369 0.584 . . . . 0.0 110.651 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.3 mt -81.64 3.26 25.97 Favored 'General case' 0 N--CA 1.457 -0.087 0 C-N-CA 123.264 0.626 . . . . 0.0 110.966 177.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.942 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 -177.68 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.037 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.7 tp -154.96 -29.44 0.11 Allowed 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 122.756 0.422 . . . . 0.0 111.943 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -55.89 -29.09 59.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 117.065 2.246 . . . . 0.0 117.065 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 70.0 m-20 -63.52 -28.26 69.83 Favored 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 120.318 -0.553 . . . . 0.0 111.868 178.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.5 mt -80.28 -38.77 18.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.287 0 C-N-CA 122.907 0.483 . . . . 0.0 109.83 176.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.4 t -65.08 -39.31 85.17 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 O-C-N 122.189 -0.32 . . . . 0.0 110.846 -178.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -66.66 -28.12 68.21 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 122.073 -0.392 . . . . 0.0 111.246 178.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.0 ttpp -74.5 -30.24 61.73 Favored 'General case' 0 C--N 1.34 0.162 0 CA-C-N 117.759 0.254 . . . . 0.0 110.845 177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.0 t -75.19 -38.79 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.93 -28.95 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.143 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.8 -29.47 74.86 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.04 -27.29 63.55 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 117.183 0.491 . . . . 0.0 110.689 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.2 mt -81.13 3.43 23.54 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 123.113 0.565 . . . . 0.0 111.016 177.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.16 7.01 88.32 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.884 -0.487 . . . . 0.0 111.884 -177.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.131 0 CA-C-N 117.961 0.881 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.056 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 63.8 tp -153.64 -28.13 0.13 Allowed 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 122.66 0.384 . . . . 0.0 111.897 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -54.05 -35.54 62.1 Favored 'General case' 0 N--CA 1.452 -0.344 0 N-CA-C 116.658 2.096 . . . . 0.0 116.658 -178.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -66.48 -22.68 66.19 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 70.5 mt -80.73 -41.4 19.84 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 174.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -69.62 -34.25 60.53 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 C-N-CA 122.088 0.155 . . . . 0.0 110.868 -179.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -62.92 -27.98 69.74 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 122.72 0.408 . . . . 0.0 111.777 179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -78.01 -29.61 49.64 Favored 'General case' 0 C--N 1.338 0.089 0 CA-C-N 117.853 0.297 . . . . 0.0 111.241 176.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.1 t -75.91 -40.6 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.129 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.377 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.0 -29.4 36.92 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.46 -29.01 73.93 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.439 -0.664 . . . . 0.0 111.439 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.08 -26.72 64.13 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 117.589 0.694 . . . . 0.0 110.745 177.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.6 mt -81.85 3.66 25.23 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.249 0.62 . . . . 0.0 111.173 177.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.83 8.45 86.73 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.839 -0.504 . . . . 0.0 111.839 -177.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.17 0 CA-C-N 117.856 0.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.043 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.4 tp -153.18 -29.37 0.14 Allowed 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 122.742 0.417 . . . . 0.0 111.762 -179.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -55.38 -31.19 61.6 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 116.699 2.111 . . . . 0.0 116.699 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -65.0 -25.14 67.73 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 178.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt -82.52 -42.57 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 C-N-CA 122.682 0.393 . . . . 0.0 110.201 174.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -68.28 -36.03 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.065 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 -176.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.1 mtmt -64.38 -25.59 68.09 Favored 'General case' 0 C--N 1.339 0.139 0 CA-C-N 118.274 0.488 . . . . 0.0 111.656 -179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 56.7 mtmt -79.87 -29.95 40.1 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.077 0.399 . . . . 0.0 111.127 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 75.3 t -74.51 -40.77 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 71.9 t -71.87 -29.41 33.45 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.18 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.61 -28.75 72.99 Favored Glycine 0 C--N 1.338 0.654 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 178.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.62 -26.3 63.42 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 117.591 0.695 . . . . 0.0 110.751 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 53.0 mt -82.91 4.82 24.11 Favored 'General case' 0 CA--C 1.53 0.2 0 C-N-CA 123.336 0.654 . . . . 0.0 111.176 177.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 6.59 88.58 Favored Glycine 0 CA--C 1.531 1.037 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.153 0 CA-C-N 117.886 0.843 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.926 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.3 tp -152.25 -28.03 0.17 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.549 0.34 . . . . 0.0 111.688 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.7 m-85 -56.5 -29.55 61.95 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 116.644 2.09 . . . . 0.0 116.644 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -66.5 -28.66 68.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.651 -0.42 . . . . 0.0 112.004 178.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.7 mt -80.17 -39.91 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.18 0 C-N-CA 122.777 0.431 . . . . 0.0 110.014 177.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.42 -40.64 87.11 Favored 'Isoleucine or valine' 0 C--N 1.34 0.174 0 N-CA-C 110.008 -0.368 . . . . 0.0 110.008 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -67.73 -26.93 66.39 Favored 'General case' 0 CA--C 1.528 0.111 0 O-C-N 122.279 -0.263 . . . . 0.0 111.372 179.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt -73.1 -32.39 64.94 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 117.832 0.287 . . . . 0.0 110.753 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.2 t -76.61 -38.04 30.34 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 63.1 t -70.48 -29.22 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.262 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 178.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.94 -28.95 73.51 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.33 -27.01 64.03 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 117.524 0.662 . . . . 0.0 110.469 177.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.2 mt -82.24 3.73 26.33 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 123.244 0.618 . . . . 0.0 111.108 178.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.42 7.65 88.03 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.061 0 CA-C-N 117.764 0.782 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.114 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 61.5 tp -82.4 -25.94 33.26 Favored 'General case' 0 CA--C 1.524 -0.034 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -56.37 -29.54 61.55 Favored 'General case' 0 N--CA 1.448 -0.529 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -67.88 -29.05 68.06 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.56 178.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.3 mt -80.07 -39.18 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.104 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 94.6 t -67.73 -40.84 84.6 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.0 mtpp -67.09 -25.83 66.42 Favored 'General case' 0 CA--C 1.529 0.155 0 O-C-N 122.072 -0.392 . . . . 0.0 111.274 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -73.88 -31.57 63.2 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 117.788 0.267 . . . . 0.0 110.632 177.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 52.9 t -76.02 -38.42 35.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 76.5 t -69.51 -29.52 41.98 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.32 -29.12 74.15 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.86 -26.63 63.35 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 117.586 0.693 . . . . 0.0 110.55 177.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.1 mt -81.7 4.79 20.55 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.05 0.54 . . . . 0.0 110.933 177.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.26 7.88 87.88 Favored Glycine 0 CA--C 1.528 0.879 0 N-CA-C 111.749 -0.54 . . . . 0.0 111.749 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.137 0 CA-C-N 117.836 0.818 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.042 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.8 tp -152.95 -28.32 0.15 Allowed 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 122.662 0.385 . . . . 0.0 111.421 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.0 m-85 -56.28 -29.31 61.0 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 116.762 2.134 . . . . 0.0 116.762 -179.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -66.75 -28.42 68.4 Favored 'General case' 0 N--CA 1.45 -0.475 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 178.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.3 mt -80.63 -39.51 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 122.803 0.441 . . . . 0.0 109.907 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -67.58 -40.17 83.72 Favored 'Isoleucine or valine' 0 C--O 1.231 0.107 0 N-CA-C 110.205 -0.295 . . . . 0.0 110.205 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -66.39 -27.18 67.66 Favored 'General case' 0 C--N 1.338 0.109 0 O-C-N 122.129 -0.357 . . . . 0.0 111.619 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -73.17 -31.06 64.0 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 117.65 0.204 . . . . 0.0 110.701 177.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 61.2 t -77.03 -38.55 28.14 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 69.7 t -69.19 -29.1 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.69 -28.96 73.37 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.571 -0.612 . . . . 0.0 111.571 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.12 63.05 Favored 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 117.515 0.657 . . . . 0.0 110.554 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.5 mt -83.44 5.16 24.7 Favored 'General case' 0 CA--C 1.529 0.145 0 C-N-CA 123.346 0.658 . . . . 0.0 111.197 177.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.94 6.39 88.42 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.84 -0.504 . . . . 0.0 111.84 -177.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.098 0 CA-C-N 117.785 0.793 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.096 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.0 tp -154.12 -27.5 0.13 Allowed 'General case' 0 C--O 1.232 0.168 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -56.72 -29.53 62.58 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 116.894 2.183 . . . . 0.0 116.894 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 -66.81 -28.87 68.72 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.048 178.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 83.4 mt -80.04 -39.65 19.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 C-N-CA 123.086 0.554 . . . . 0.0 109.804 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 97.3 t -66.51 -41.28 88.26 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -179.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -67.07 -27.01 67.01 Favored 'General case' 0 N--CA 1.456 -0.151 0 O-C-N 122.253 -0.279 . . . . 0.0 111.614 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.3 -32.63 64.73 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 122.271 0.229 . . . . 0.0 110.697 177.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.6 t -75.79 -38.21 36.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.08 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 64.4 t -70.17 -28.94 37.7 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.7 -27.89 72.58 Favored Glycine 0 CA--C 1.528 0.854 0 N-CA-C 111.496 -0.641 . . . . 0.0 111.496 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.54 -26.54 62.69 Favored 'General case' 0 N--CA 1.455 -0.2 0 CA-C-N 117.479 0.64 . . . . 0.0 110.587 177.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 60.1 mt -81.48 3.54 24.38 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 123.318 0.647 . . . . 0.0 111.082 178.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.17 7.02 88.31 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -177.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.018 0 O-C-N 121.772 -0.84 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.056 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 60.8 tp -83.87 -25.6 30.11 Favored 'General case' 0 C--N 1.334 -0.103 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -56.87 -29.37 62.86 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 116.494 2.035 . . . . 0.0 116.494 -178.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -66.78 -29.21 69.1 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 120.8 -0.36 . . . . 0.0 111.732 177.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -79.82 -36.55 17.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.337 0 C-N-CA 122.826 0.45 . . . . 0.0 109.899 176.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 90.0 t -64.7 -40.68 89.9 Favored 'Isoleucine or valine' 0 C--N 1.338 0.07 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -67.54 -27.75 67.22 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 117.805 0.275 . . . . 0.0 111.173 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -74.28 -31.61 62.59 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 117.931 0.332 . . . . 0.0 111.03 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 47.6 t -74.72 -37.95 43.84 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.6 t -71.85 -29.21 32.73 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.39 -29.49 74.72 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 179.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.19 -26.81 65.02 Favored 'General case' 0 N--CA 1.456 -0.161 0 CA-C-N 117.295 0.547 . . . . 0.0 110.68 177.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.9 mt -82.73 3.77 27.86 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 122.93 0.492 . . . . 0.0 111.064 178.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 6.54 88.69 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.066 0 CA-C-N 117.632 0.716 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.012 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 68.0 tp -154.94 -29.24 0.11 Allowed 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 122.687 0.395 . . . . 0.0 111.722 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -55.63 -29.12 58.65 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 117.256 2.317 . . . . 0.0 117.256 -178.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 69.7 m-20 -63.76 -29.07 70.32 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 120.051 -0.66 . . . . 0.0 111.59 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.0 mt -80.64 -37.23 16.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 123.141 0.576 . . . . 0.0 109.78 176.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -63.96 -42.27 95.21 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.094 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -69.02 -27.15 65.42 Favored 'General case' 0 N--CA 1.457 -0.091 0 O-C-N 122.203 -0.31 . . . . 0.0 110.945 178.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -71.92 -31.81 66.73 Favored 'General case' 0 N--CA 1.456 -0.151 0 C-N-CA 122.569 0.348 . . . . 0.0 110.599 177.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 51.3 t -75.49 -36.92 36.49 Favored 'Isoleucine or valine' 0 C--N 1.339 0.12 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.0 t -70.15 -29.37 39.41 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.078 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.71 -28.19 72.2 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 178.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.61 -27.02 63.76 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 117.239 0.519 . . . . 0.0 110.675 177.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -82.72 4.57 24.54 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.261 0.625 . . . . 0.0 111.131 178.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.92 6.05 89.27 Favored Glycine 0 CA--C 1.528 0.885 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.115 0 CA-C-N 117.798 0.799 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.083 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.6 tp -154.86 -30.32 0.11 Allowed 'General case' 0 CA--C 1.528 0.111 0 C-N-CA 122.555 0.342 . . . . 0.0 111.634 179.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . 0.259 30.7 m-85 -55.26 -29.08 57.39 Favored 'General case' 0 N--CA 1.454 -0.256 0 N-CA-C 117.309 2.337 . . . . 0.0 117.309 -178.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -62.65 -28.61 70.04 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 120.517 -0.473 . . . . 0.0 111.667 177.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 93.0 mt -80.89 -38.31 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.119 0 C-N-CA 123.141 0.577 . . . . 0.0 110.005 175.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.4 t -63.18 -35.67 72.87 Favored 'Isoleucine or valine' 0 C--O 1.23 0.073 0 N-CA-C 111.572 0.212 . . . . 0.0 111.572 -177.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -64.67 -27.4 68.9 Favored 'General case' 0 N--CA 1.457 -0.098 0 O-C-N 121.861 -0.525 . . . . 0.0 111.139 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -76.22 -29.82 57.71 Favored 'General case' 0 N--CA 1.461 0.092 0 CA-C-N 117.716 0.234 . . . . 0.0 110.715 177.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 71.9 t -75.02 -40.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.165 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 74.6 t -68.91 -29.32 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.1 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.08 -29.51 74.61 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.79 -0.524 . . . . 0.0 111.79 178.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.06 -27.02 64.29 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.384 0.592 . . . . 0.0 110.857 177.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.0 mt -82.25 3.76 26.21 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.193 0.597 . . . . 0.0 111.099 177.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.97 6.21 89.11 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.134 0 CA-C-N 117.671 0.736 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.041 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.6 tp -152.68 -28.73 0.15 Allowed 'General case' 0 CA--C 1.527 0.089 0 C-N-CA 122.814 0.446 . . . . 0.0 111.868 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -55.94 -29.63 60.42 Favored 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 117.03 2.233 . . . . 0.0 117.03 -179.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -67.05 -29.35 69.11 Favored 'General case' 0 N--CA 1.454 -0.265 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.126 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 79.3 mt -80.23 -38.45 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.229 0 C-N-CA 122.786 0.434 . . . . 0.0 109.906 177.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 82.6 t -65.75 -41.42 90.29 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.109 0 N-CA-C 109.346 -0.612 . . . . 0.0 109.346 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.8 mtpp -68.82 -27.5 65.9 Favored 'General case' 0 C--N 1.334 -0.103 0 O-C-N 122.356 -0.215 . . . . 0.0 111.363 178.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -71.94 -31.88 66.77 Favored 'General case' 0 CA--C 1.53 0.177 0 C-N-CA 122.359 0.263 . . . . 0.0 110.843 177.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.19 -38.12 33.55 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.9 t -69.28 -29.27 41.78 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 177.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.59 -28.16 72.07 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -72.07 -26.01 62.0 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 117.515 0.657 . . . . 0.0 110.41 178.137 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 59.4 mt -82.48 4.74 23.11 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.219 0.608 . . . . 0.0 111.251 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.26 7.36 87.79 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 -177.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.084 0 CA-C-N 118.017 0.909 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.021 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.3 tp -154.52 -30.47 0.11 Allowed 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 122.563 0.345 . . . . 0.0 111.854 -179.489 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -55.87 -29.37 59.82 Favored 'General case' 0 N--CA 1.454 -0.258 0 N-CA-C 116.67 2.1 . . . . 0.0 116.67 -177.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.6 m-20 -63.32 -28.4 69.98 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 120.479 -0.489 . . . . 0.0 111.823 177.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 92.4 mt -80.06 -36.83 17.12 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -62.68 -34.84 67.61 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 O-C-N 122.157 -0.339 . . . . 0.0 110.725 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.01 -28.19 69.93 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 117.937 0.335 . . . . 0.0 111.413 177.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -78.82 -29.67 44.91 Favored 'General case' 0 C--N 1.339 0.131 0 CA-C-N 117.702 0.228 . . . . 0.0 110.731 177.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 78.8 t -74.46 -40.05 48.56 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.142 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 77.3 t -71.66 -29.0 32.7 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.089 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.06 -29.17 74.13 Favored Glycine 0 C--N 1.339 0.699 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.2 -26.17 64.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 117.56 0.68 . . . . 0.0 110.763 177.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.1 mt -83.21 5.23 23.58 Favored 'General case' 0 CA--C 1.529 0.156 0 C-N-CA 123.196 0.599 . . . . 0.0 111.238 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 6.12 89.05 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -177.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.133 0 CA-C-N 117.757 0.778 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.012 0 N-CA-C 111.32 -0.712 . . . . 0.0 111.32 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.8 tp -154.34 -29.4 0.12 Allowed 'General case' 0 CA--C 1.529 0.14 0 C-N-CA 122.466 0.307 . . . . 0.0 111.73 179.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -56.08 -29.12 60.11 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 116.88 2.178 . . . . 0.0 116.88 -178.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -65.58 -28.05 68.86 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.959 178.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 85.4 mt -80.02 -37.31 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 175.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.7 -40.35 88.71 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -66.96 -28.49 68.32 Favored 'General case' 0 N--CA 1.457 -0.093 0 O-C-N 122.075 -0.391 . . . . 0.0 111.227 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.86 -33.7 62.14 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 117.762 0.255 . . . . 0.0 110.75 178.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 49.8 t -73.41 -39.52 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.131 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.9 t -71.2 -29.44 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.086 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.01 -29.46 74.95 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.67 -26.1 63.29 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 117.346 0.573 . . . . 0.0 110.751 178.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.79 3.31 26.3 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.933 0.493 . . . . 0.0 111.189 177.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.94 8.79 86.2 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -177.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.029 0 CA-C-N 117.688 0.744 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.027 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.6 tp -153.71 -28.05 0.13 Allowed 'General case' 0 CA--C 1.527 0.077 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -56.54 -29.44 61.95 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 116.736 2.125 . . . . 0.0 116.736 -178.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -65.57 -28.71 69.34 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 120.443 -0.503 . . . . 0.0 112.051 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 90.8 mt -80.47 -35.16 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 C-N-CA 123.003 0.521 . . . . 0.0 110.045 176.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 85.4 t -63.57 -41.03 91.22 Favored 'Isoleucine or valine' 0 C--O 1.23 0.039 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 178.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -70.06 -28.79 65.74 Favored 'General case' 0 C--N 1.34 0.152 0 O-C-N 122.303 -0.248 . . . . 0.0 110.937 177.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -71.76 -32.45 67.7 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 122.511 0.324 . . . . 0.0 110.927 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 39.6 t -73.69 -36.35 46.52 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 178.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 58.5 t -71.04 -29.47 37.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 177.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.28 -28.67 73.33 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.82 -25.66 62.95 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.33 0.565 . . . . 0.0 110.867 178.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.0 mt -81.75 3.99 23.67 Favored 'General case' 0 C--O 1.233 0.193 0 C-N-CA 123.069 0.547 . . . . 0.0 111.128 177.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.97 7.13 88.29 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 -177.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.104 0 CA-C-N 118.054 0.927 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.921 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 68.4 tp -154.18 -28.64 0.12 Allowed 'General case' 0 CA--C 1.528 0.112 0 C-N-CA 122.466 0.306 . . . . 0.0 111.666 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -56.12 -29.14 60.24 Favored 'General case' 0 N--CA 1.451 -0.384 0 N-CA-C 117.218 2.303 . . . . 0.0 117.218 -178.227 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -65.38 -28.36 69.22 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.786 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 89.9 mt -79.91 -36.74 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 176.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 86.0 t -63.83 -40.1 87.81 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 31.4 mmmt -67.46 -28.56 67.98 Favored 'General case' 0 N--CA 1.456 -0.173 0 O-C-N 122.341 -0.224 . . . . 0.0 111.33 177.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.57 -32.22 62.33 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.155 0.182 . . . . 0.0 111.029 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 46.8 t -73.38 -38.16 52.81 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 53.7 t -71.51 -29.19 34.01 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.53 -28.99 73.3 Favored Glycine 0 CA--C 1.529 0.918 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.07 -26.75 64.15 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 117.592 0.696 . . . . 0.0 110.421 177.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 55.7 mt -82.88 3.91 27.77 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.292 0.637 . . . . 0.0 111.128 177.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.5 6.74 88.96 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -177.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 -0.042 0 CA-C-N 117.595 0.698 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.073 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 66.5 tp -154.11 -28.48 0.12 Allowed 'General case' 0 N--CA 1.455 -0.216 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.7 m-85 -56.16 -29.29 60.59 Favored 'General case' 0 N--CA 1.455 -0.178 0 N-CA-C 117.064 2.246 . . . . 0.0 117.064 -178.103 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -65.98 -28.1 68.63 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.51 -0.476 . . . . 0.0 112.114 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 81.3 mt -80.04 -37.35 17.63 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.263 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 176.364 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 98.1 t -63.43 -40.49 89.25 Favored 'Isoleucine or valine' 0 C--N 1.339 0.121 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 179.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -67.42 -28.52 67.97 Favored 'General case' 0 N--CA 1.455 -0.186 0 O-C-N 122.289 -0.257 . . . . 0.0 111.165 177.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.8 ttmm -74.19 -32.43 63.07 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-N 117.709 0.231 . . . . 0.0 110.954 178.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.6 t -75.33 -38.08 39.87 Favored 'Isoleucine or valine' 0 C--N 1.338 0.081 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 178.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 54.9 t -70.16 -29.08 38.25 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 177.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.98 -28.76 73.25 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.57 -26.61 63.61 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 117.705 0.753 . . . . 0.0 110.642 177.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 52.0 mt -82.83 4.34 25.83 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.193 0.597 . . . . 0.0 111.295 177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.27 6.73 88.49 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 -178.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.12 0 CA-C-N 117.807 0.804 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.86 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 65.9 tp -154.93 -30.32 0.1 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 122.698 -0.295 . . . . 0.0 111.73 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -55.72 -29.64 59.81 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 116.919 2.192 . . . . 0.0 116.919 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -63.21 -27.63 69.49 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 120.592 -0.443 . . . . 0.0 112.153 177.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 84.1 mt -80.6 -36.6 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 C-N-CA 123.177 0.591 . . . . 0.0 109.944 175.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -62.56 -34.16 63.5 Favored 'Isoleucine or valine' 0 C--O 1.227 -0.106 0 O-C-N 122.33 -0.231 . . . . 0.0 110.598 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.2 mptp? -63.86 -26.42 68.6 Favored 'General case' 0 C--O 1.232 0.143 0 O-C-N 122.253 -0.28 . . . . 0.0 111.395 177.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 33.3 mmtp -75.42 -29.92 59.88 Favored 'General case' 0 C--N 1.337 0.051 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 177.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 95.5 t -76.87 -41.77 32.55 Favored 'Isoleucine or valine' 0 C--N 1.339 0.116 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 80.9 t -69.81 -29.46 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.159 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.1 -29.45 74.45 Favored Glycine 0 CA--C 1.528 0.887 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.492 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.45 -27.25 64.1 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 117.492 0.646 . . . . 0.0 110.757 178.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.7 mt -81.55 3.87 23.42 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.406 0.682 . . . . 0.0 111.101 177.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.49 6.37 88.68 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 -177.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.197 0 CA-C-N 117.712 0.756 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.378 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -148.16 -28.85 0.32 Allowed 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 122.76 0.424 . . . . 0.0 111.021 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -55.94 -29.23 59.81 Favored 'General case' 0 N--CA 1.454 -0.246 0 N-CA-C 117.183 2.29 . . . . 0.0 117.183 -179.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -62.47 -27.48 69.16 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 177.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 97.1 mt -80.02 -36.88 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.275 0 C-N-CA 123.162 0.585 . . . . 0.0 109.476 176.097 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -66.99 -41.85 87.9 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 O-C-N 122.418 -0.176 . . . . 0.0 110.886 -178.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 34.9 mmtp -67.51 -26.99 66.61 Favored 'General case' 0 CA--C 1.527 0.092 0 O-C-N 122.24 -0.287 . . . . 0.0 111.028 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -73.46 -31.75 63.95 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 117.657 0.208 . . . . 0.0 110.467 178.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 50.8 t -76.19 -37.84 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.098 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 57.3 t -69.61 -29.0 39.73 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.58 -29.36 74.41 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 179.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.4 -26.41 63.68 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 117.482 0.641 . . . . 0.0 110.226 178.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.4 mt -82.7 4.0 26.81 Favored 'General case' 0 CA--C 1.529 0.173 0 C-N-CA 123.218 0.607 . . . . 0.0 111.074 178.002 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.43 6.8 88.95 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 111.629 -0.588 . . . . 0.0 111.629 -177.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.333 -0.136 0 CA-C-N 117.657 0.728 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.064 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -149.94 -30.78 0.22 Allowed 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 122.853 0.461 . . . . 0.0 110.891 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -55.15 -29.58 58.07 Favored 'General case' 0 N--CA 1.456 -0.167 0 N-CA-C 117.236 2.309 . . . . 0.0 117.236 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -63.82 -25.81 68.34 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 178.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 86.5 mt -79.48 -36.1 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 175.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 43.5 t -66.04 -35.81 75.95 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.085 0 C-N-CA 122.317 0.247 . . . . 0.0 110.987 -179.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.3 mptp? -65.13 -29.01 69.83 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.102 -0.374 . . . . 0.0 110.75 177.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -76.5 -29.73 56.94 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 117.934 0.334 . . . . 0.0 110.826 177.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 53.8 t -73.54 -39.0 53.6 Favored 'Isoleucine or valine' 0 C--O 1.228 -0.055 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 177.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 62.4 t -70.1 -29.26 39.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.121 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 176.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.47 -28.82 73.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.05 -26.67 64.14 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 117.493 0.646 . . . . 0.0 110.601 177.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 56.3 mt -82.44 3.8 26.76 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 123.295 0.638 . . . . 0.0 111.072 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 8.03 87.72 Favored Glycine 0 CA--C 1.528 0.862 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -177.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.334 -0.097 0 CA-C-N 117.721 0.761 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.8 tp -153.59 -29.5 0.13 Allowed 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 111.703 0.26 . . . . 0.0 111.703 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . 0.252 27.9 m-85 -57.52 -25.37 59.76 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 117.57 2.434 . . . . 0.0 117.57 -178.315 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 47.8 t0 -66.21 -29.3 69.53 Favored 'General case' 0 N--CA 1.455 -0.193 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 91.8 mt -80.33 -37.73 17.45 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.019 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.0 t -63.21 -37.88 80.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 O-C-N 122.349 -0.219 . . . . 0.0 110.84 -179.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm -65.76 -28.8 69.29 Favored 'General case' 0 C--N 1.34 0.153 0 O-C-N 122.194 -0.316 . . . . 0.0 111.236 178.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 4.4 ttmp? -75.25 -31.64 60.86 Favored 'General case' 0 CA--C 1.53 0.179 0 CA-C-N 117.751 0.25 . . . . 0.0 110.694 178.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 54.2 t -73.96 -39.09 50.91 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.4 -29.52 39.26 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.57 -29.08 73.59 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -69.85 -26.97 64.46 Favored 'General case' 0 N--CA 1.454 -0.228 0 CA-C-N 117.369 0.584 . . . . 0.0 110.651 177.481 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 54.3 mt -81.64 3.26 25.97 Favored 'General case' 0 N--CA 1.457 -0.087 0 C-N-CA 123.264 0.626 . . . . 0.0 110.966 177.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.47 7.14 87.94 Favored Glycine 0 CA--C 1.529 0.942 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 -177.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.332 -0.173 0 CA-C-N 117.554 0.677 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_